<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pathogens</journal-id><journal-id journal-id-type="iso-abbrev">Pathogens</journal-id><journal-id journal-id-type="publisher-id">pathogens</journal-id><journal-title-group><journal-title>Pathogens</journal-title></journal-title-group><issn pub-type="epub">2076-0817</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6963926</article-id><article-id pub-id-type="doi">10.3390/pathogens8040168</article-id><article-id pub-id-type="publisher-id">pathogens-08-00168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Host Single Nucleotide Polymorphisms Modulating Influenza A Virus Disease in Humans</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nogales</surname><given-names>Aitor</given-names></name><xref ref-type="aff" rid="af1-pathogens-08-00168">1</xref><xref rid="c1-pathogens-08-00168" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7888-7372</contrib-id><name><surname>L. DeDiego</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="af2-pathogens-08-00168">2</xref><xref rid="c1-pathogens-08-00168" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pathogens-08-00168"><label>1</label>Center for Animal Health Research, INIA-CISA, 28130 Madrid, Spain</aff><aff id="af2-pathogens-08-00168"><label>2</label>Department of Molecular and Cell Biology, Centro Nacional de Biotecnolog&#x000ed;a (CNB-CSIC), Campus Universidad Aut&#x000f3;noma de Madrid, 28049 Madrid, Spain</aff><author-notes><corresp id="c1-pathogens-08-00168"><label>*</label>Correspondence: <email>nogales.aitor@inia.es</email> (A.N.); <email>Marta.Lopez@cnb.csic.es</email> (M.L.D.)</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>8</volume><issue>4</issue><elocation-id>168</elocation-id><history><date date-type="received"><day>11</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>A large number of human genes associated with viral infections contain single nucleotide polymorphisms (SNPs), which represent a genetic variation caused by the change of a single nucleotide in the DNA sequence. SNPs are located in coding or non-coding genomic regions and can affect gene expression or protein function by different mechanisms. Furthermore, they have been linked to multiple human diseases, highlighting their medical relevance. Therefore, the identification and analysis of this kind of polymorphisms in the human genome has gained high importance in the research community, and an increasing number of studies have been published during the last years. As a consequence of this exhaustive exploration, an association between the presence of some specific SNPs and the susceptibility or severity of many infectious diseases in some risk population groups has been found. In this review, we discuss the relevance of SNPs that are important to understand the pathology derived from influenza A virus (IAV) infections in humans and the susceptibility of some individuals to suffer more severe symptoms. We also discuss the importance of SNPs for IAV vaccine effectiveness.</p></abstract><kwd-group><kwd>Influenza A virus (IAV)</kwd><kwd>innate immunity</kwd><kwd>single nucleotide polymorphisms (SNPs)</kwd><kwd>Influenza vaccine</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pathogens-08-00168"><title>1. Introduction</title><sec id="sec1dot1-pathogens-08-00168"><title>1.1. Influenza A Virus (IAV)</title><p>Influenza A viruses (IAV) belong to the <italic>Orthomyxoviridae</italic> family, and they contain a single-stranded (ss) negative-sense viral (v)RNA genome formed by eight segments that are encapsidated into particles with an envelope (<xref ref-type="fig" rid="pathogens-08-00168-f001">Figure 1</xref>A). Each of the vRNA segments contains a long central coding region flanked at 5&#x02032; and 3&#x02032; termini by non-coding regions (NCRs), which work as promoters to initiate viral RNA synthesis (transcription and replication). Moreover, the packaging signals playing a role in the efficient encapsidation of the viral segments into nascent virions, are located at the 3&#x02032; and 5&#x02032; end of the coding regions (<xref ref-type="fig" rid="pathogens-08-00168-f001">Figure 1</xref>B) [<xref rid="B1-pathogens-08-00168" ref-type="bibr">1</xref>]. Structurally, vRNAs form viral ribonucleoprotein complexes (vRNPs), where vRNAs are coated with multiple subunits of the viral nucleoprotein (NP) and are associated with the heterotrimeric polymerase, which contains the polymerase basic 2 and 1 (PB2 and PB1, respectively) and acidic (PA) proteins (<xref ref-type="fig" rid="pathogens-08-00168-f001">Figure 1</xref>A) [<xref rid="B2-pathogens-08-00168" ref-type="bibr">2</xref>,<xref rid="B3-pathogens-08-00168" ref-type="bibr">3</xref>,<xref rid="B4-pathogens-08-00168" ref-type="bibr">4</xref>]. Each vRNP acts as an independent transcription-replication unit using an uncommon mechanism among negative-sense RNA viruses, given that viral RNA synthesis occurs in the infected-cells nucleus. vRNAs are used as templates by the viral polymerase to synthesize two positive-sense RNA molecules, the complementary RNAs (cRNAs), from which the same viral polymerase synthesizes more copies of genomic vRNA, and the mRNAs for viral protein synthesis [<xref rid="B1-pathogens-08-00168" ref-type="bibr">1</xref>,<xref rid="B2-pathogens-08-00168" ref-type="bibr">2</xref>,<xref rid="B3-pathogens-08-00168" ref-type="bibr">3</xref>,<xref rid="B4-pathogens-08-00168" ref-type="bibr">4</xref>,<xref rid="B5-pathogens-08-00168" ref-type="bibr">5</xref>,<xref rid="B6-pathogens-08-00168" ref-type="bibr">6</xref>]. The small IAV genome encodes for up to 16 viral proteins through multiple mechanisms, although there are some differences between strains. For that genome plasticity, IAV take advantage of multiple strategies, such as alternative splicing, frameshift mechanisms, and overlapping open reading frames (ORFs) [<xref rid="B7-pathogens-08-00168" ref-type="bibr">7</xref>,<xref rid="B8-pathogens-08-00168" ref-type="bibr">8</xref>,<xref rid="B9-pathogens-08-00168" ref-type="bibr">9</xref>]. In addition, the coding capability of the viral genome is extended by encoding multifunctional proteins that act at different steps during virus infection.</p><p>The viral envelope is decorated with the two viral glycoproteins hemagglutinin (HA) and neuraminidase (NA) at a ratio of approximately four to one, respectively [<xref rid="B10-pathogens-08-00168" ref-type="bibr">10</xref>,<xref rid="B11-pathogens-08-00168" ref-type="bibr">11</xref>]. HA envelope protein mediates virus entry by binding to sialic acid-containing cell receptors, and then fusing endosomal and viral membranes during endocytosis [<xref rid="B12-pathogens-08-00168" ref-type="bibr">12</xref>,<xref rid="B13-pathogens-08-00168" ref-type="bibr">13</xref>], while NA is required for viral release from infected host cells, and it acts as a receptor destroying enzyme, cleaving terminal sialic acid residues from glycoproteins present at the cell surface [<xref rid="B14-pathogens-08-00168" ref-type="bibr">14</xref>,<xref rid="B15-pathogens-08-00168" ref-type="bibr">15</xref>,<xref rid="B16-pathogens-08-00168" ref-type="bibr">16</xref>]. The matrix 2 (M2) protein is also found in the viral membrane, although in much lower abundance than HA or NA glycoproteins. M2 is a small transmembrane protein that forms a proton-selective ion channel in the viral envelope. M2 promotes uncoating of the vRNPs after membrane fusion and the protein has also an essential role in viral assembly and release [<xref rid="B17-pathogens-08-00168" ref-type="bibr">17</xref>]. Under the viral envelop, there is an inner shell composed of the matrix 1 (M1) protein, which interacts in the virion with the vRNP and the HA and NA proteins. M1 apart from being a membrane-associated scaffold factor of the virion, acts as a crucial factor for different viral processes during infection, including virion assembly and budding [<xref rid="B18-pathogens-08-00168" ref-type="bibr">18</xref>,<xref rid="B19-pathogens-08-00168" ref-type="bibr">19</xref>,<xref rid="B20-pathogens-08-00168" ref-type="bibr">20</xref>]. The nonstructural (NS) gene or segment 8 of IAV encodes an mRNA transcript that is alternatively spliced to express two viral proteins, the nonstructural protein 1 (NS1), produced from a continuous primary transcript, and the nuclear export protein (NEP), which is produced by an alternatively processed transcript, using a weak 5&#x02032; splice site. NEP is also located in the virion and may interact with M1 in the viral particle [<xref rid="B21-pathogens-08-00168" ref-type="bibr">21</xref>,<xref rid="B22-pathogens-08-00168" ref-type="bibr">22</xref>,<xref rid="B23-pathogens-08-00168" ref-type="bibr">23</xref>] (<xref ref-type="fig" rid="pathogens-08-00168-f001">Figure 1</xref>A). During the infection, NEP is responsible for the nuclear export of synthetized vRNP, ensuring that the vRNPs are available for packaging [<xref rid="B24-pathogens-08-00168" ref-type="bibr">24</xref>]. Moreover, NEP has also other functions during IAV infection, contributing to viral budding and to regulate viral RNA synthesis. NS1 is a multifunctional protein and a key viral factor that counteracts the host antiviral responses. NS1 has been shown to inhibit the production of interferon (IFN), the activity and expression of multiple interferon-induced genes (ISG) and the processing and nuclear transport of host mRNAs causing cellular shut-off [<xref rid="B25-pathogens-08-00168" ref-type="bibr">25</xref>,<xref rid="B26-pathogens-08-00168" ref-type="bibr">26</xref>]. Segment 3 of IAV also encodes two proteins, the polymerase component PA and PA-X. PA is translated directly from the PA mRNA, whereas PA-X is translated using a +1 frameshift mechanism from the same open reading frame (ORF) [<xref rid="B9-pathogens-08-00168" ref-type="bibr">9</xref>]. Synergistically with NS1, PA-X is also able to block the cellular antiviral responses by inhibiting host protein expression. Moreover, the PA-X protein has been shown to modulate host inflammation, immune responses, apoptosis, and virus pathogenesis [<xref rid="B25-pathogens-08-00168" ref-type="bibr">25</xref>,<xref rid="B26-pathogens-08-00168" ref-type="bibr">26</xref>,<xref rid="B27-pathogens-08-00168" ref-type="bibr">27</xref>,<xref rid="B28-pathogens-08-00168" ref-type="bibr">28</xref>,<xref rid="B29-pathogens-08-00168" ref-type="bibr">29</xref>,<xref rid="B30-pathogens-08-00168" ref-type="bibr">30</xref>]. </p></sec><sec id="sec1dot2-pathogens-08-00168"><title>1.2. Influenza Virus Importance in Human Health</title><p>Human IAV infections cause contagious respiratory diseases associated with mild to severe respiratory illness or even death, and they are considered as an important public health threat worldwide, which also results in significant economic losses [<xref rid="B31-pathogens-08-00168" ref-type="bibr">31</xref>,<xref rid="B32-pathogens-08-00168" ref-type="bibr">32</xref>,<xref rid="B33-pathogens-08-00168" ref-type="bibr">33</xref>]. IAV are divided into multiple subtypes, based on the HA and NA glycoproteins. Currently, there are 18 HA (H1 to H18) and 11 NA (N1 to N11), but the growing IAV surveillance programs and sequencing technologies could increase the number of subtypes in the following years. IAV can infect a wide range of avian and mammalian species, although the natural reservoirs of IAV are shorebirds and wild waterfowls [<xref rid="B34-pathogens-08-00168" ref-type="bibr">34</xref>,<xref rid="B35-pathogens-08-00168" ref-type="bibr">35</xref>,<xref rid="B36-pathogens-08-00168" ref-type="bibr">36</xref>,<xref rid="B37-pathogens-08-00168" ref-type="bibr">37</xref>]. Among all the HA and NA subtypes, only H3N2 and H1N1 IAV subtypes are circulating in human beings and they are responsible for annual recurrent epidemics that affect the entire world [<xref rid="B38-pathogens-08-00168" ref-type="bibr">38</xref>,<xref rid="B39-pathogens-08-00168" ref-type="bibr">39</xref>]. Seasonal influenza infections are prevented and controlled through annual vaccination campaigns to decrease IAV infections and viral transmission as well as to reduce their negative impact in the global economy. However, although vaccination remains the most effective approach to protect the population from seasonal infections, the effectiveness of current vaccination approaches is suboptimal [<xref rid="B16-pathogens-08-00168" ref-type="bibr">16</xref>,<xref rid="B31-pathogens-08-00168" ref-type="bibr">31</xref>,<xref rid="B32-pathogens-08-00168" ref-type="bibr">32</xref>,<xref rid="B33-pathogens-08-00168" ref-type="bibr">33</xref>,<xref rid="B39-pathogens-08-00168" ref-type="bibr">39</xref>,<xref rid="B40-pathogens-08-00168" ref-type="bibr">40</xref>,<xref rid="B41-pathogens-08-00168" ref-type="bibr">41</xref>,<xref rid="B42-pathogens-08-00168" ref-type="bibr">42</xref>,<xref rid="B43-pathogens-08-00168" ref-type="bibr">43</xref>,<xref rid="B44-pathogens-08-00168" ref-type="bibr">44</xref>]. Thus, the production of improved prophylactic approaches, including universal vaccines, are highly desired. Concerns associated with IAV are further aggravated by the adaptive capacity of the viruses to infect new hosts or escape to the immune system, as well as their ability to transmit efficiently in the population and the limited therapeutic options to treat viral infections [<xref rid="B14-pathogens-08-00168" ref-type="bibr">14</xref>,<xref rid="B16-pathogens-08-00168" ref-type="bibr">16</xref>,<xref rid="B25-pathogens-08-00168" ref-type="bibr">25</xref>,<xref rid="B45-pathogens-08-00168" ref-type="bibr">45</xref>].</p><p>Because of the ability of IAV to modify their genome using two main evolutionary mechanisms, antigenic drift and shift, viruses encoding novel antigenic proteins to which the population has limited or no preexisting immunity can be generated [<xref rid="B10-pathogens-08-00168" ref-type="bibr">10</xref>,<xref rid="B31-pathogens-08-00168" ref-type="bibr">31</xref>,<xref rid="B37-pathogens-08-00168" ref-type="bibr">37</xref>,<xref rid="B40-pathogens-08-00168" ref-type="bibr">40</xref>]. For that reason, seasonal vaccines have to be reformulated yearly to guarantee that the viral glycoproteins (HA and NA) in the vaccine match seasonal viruses circulating worldwide [<xref rid="B38-pathogens-08-00168" ref-type="bibr">38</xref>,<xref rid="B43-pathogens-08-00168" ref-type="bibr">43</xref>,<xref rid="B46-pathogens-08-00168" ref-type="bibr">46</xref>]. In addition, IAV variability can lead to the generation of new virus strains with pandemic potential. For example, the first IAV pandemic of this century occurred in 2009 and it is estimated that in approximately one year, the pandemic 2009 H1N1 (pH1N1) IAV infected more than 600,000 human beings, causing near 16,000 deaths in over 200 countries [<xref rid="B40-pathogens-08-00168" ref-type="bibr">40</xref>,<xref rid="B41-pathogens-08-00168" ref-type="bibr">41</xref>]. In addition, although only H1N1 and H3N2 are circulating in humans, the avian H5, H7, and H9 subtypes eventually cross the species barrier to infect humans, representing a new and serious public health problem [<xref rid="B13-pathogens-08-00168" ref-type="bibr">13</xref>,<xref rid="B37-pathogens-08-00168" ref-type="bibr">37</xref>,<xref rid="B47-pathogens-08-00168" ref-type="bibr">47</xref>,<xref rid="B48-pathogens-08-00168" ref-type="bibr">48</xref>,<xref rid="B49-pathogens-08-00168" ref-type="bibr">49</xref>].</p></sec><sec id="sec1dot3-pathogens-08-00168"><title>1.3. Innate Immunity in IAV Infections</title><p>The cellular defense mechanisms provided by the innate immune system are a formidable barrier to inhibit virus infections [<xref rid="B50-pathogens-08-00168" ref-type="bibr">50</xref>] and involve the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs). This recognition leads to the activation of signaling pathways and the production and secretion of IFNs of type I (IFN&#x003b1; and IFN&#x003b2;) and III (IFN&#x003bb;2 or IL-28A, IFN&#x003bb;3 or IL-28B, and IFN&#x003bb;1 or IL-29), and chemokines and cytokines involved in inflammatory processes [<xref rid="B50-pathogens-08-00168" ref-type="bibr">50</xref>]. IAV RNAs are mainly recognized by the endosomal, membrane-associated PRR Toll-like receptors (TLRs) 3 (double-stranded RNAs, dsRNAs) or 7/8 (ssRNAs), respectively [<xref rid="B50-pathogens-08-00168" ref-type="bibr">50</xref>,<xref rid="B51-pathogens-08-00168" ref-type="bibr">51</xref>], by the cytoplasmic PRR retinoic acid-inducible gene I (RIG-I), which detects dsRNA and 5&#x02032;- triphosphates of the negative ssRNA viral genome [<xref rid="B50-pathogens-08-00168" ref-type="bibr">50</xref>,<xref rid="B52-pathogens-08-00168" ref-type="bibr">52</xref>], generated during replication of multiple viruses, by the NOD-like receptor family member NOD-, LRR- and pyrin domain-containing 3 (NLRP3), which recognizes various stimuli (see below) [<xref rid="B53-pathogens-08-00168" ref-type="bibr">53</xref>] and by the absent in melanoma 2 (AIM2) protein, recognizing not well-characterized influenza stimuli [<xref rid="B54-pathogens-08-00168" ref-type="bibr">54</xref>]. The result of PRR detection of viral PAMPs is the activation of multiple transcription factors, such as the nuclear factor kappa &#x003b2; (NF-&#x003ba;B), the activator protein 1 (AP-1), and IFN regulatory factors (IRF)-3 and IRF-7, which are responsible for the transcription of IFNs [<xref rid="B50-pathogens-08-00168" ref-type="bibr">50</xref>,<xref rid="B55-pathogens-08-00168" ref-type="bibr">55</xref>,<xref rid="B56-pathogens-08-00168" ref-type="bibr">56</xref>] and pro-inflammatory cytokines [<xref rid="B57-pathogens-08-00168" ref-type="bibr">57</xref>]. </p><p>Secreted type I and III IFNs signal through different receptors in a paracrine or autocrine way to induce the transcription of IFN-stimulated genes (ISGs), several of which counteract viral replication [<xref rid="B50-pathogens-08-00168" ref-type="bibr">50</xref>,<xref rid="B56-pathogens-08-00168" ref-type="bibr">56</xref>,<xref rid="B58-pathogens-08-00168" ref-type="bibr">58</xref>]. Just as an example mentioned below, IFITM3 is an ISG playing antiviral roles against influenza virus infection and other viruses [<xref rid="B59-pathogens-08-00168" ref-type="bibr">59</xref>]. Type I and III IFNs signaling pathways lead to the post-translational phosphorylation of the signal transducer and activator of transcription (STAT) 1 and 2 transcription factors [<xref rid="B60-pathogens-08-00168" ref-type="bibr">60</xref>], being the tyrosine kinase 2 (TYK2) and Janus protein tyrosine kinase 1 (JAK1) critical for the phosphorylation [<xref rid="B61-pathogens-08-00168" ref-type="bibr">61</xref>]. Moreover, STAT1 is phosphorylated by IKK&#x003b5; during IFN signaling and this step is important for the IFN-inducible innate immune response [<xref rid="B62-pathogens-08-00168" ref-type="bibr">62</xref>,<xref rid="B63-pathogens-08-00168" ref-type="bibr">63</xref>]. Upon phosphorylation, STAT1 and STAT2 associate with IRF-9 forming the heterotrimeric ISG factor 3 (ISGF3) complex [<xref rid="B60-pathogens-08-00168" ref-type="bibr">60</xref>]. This heterotrimeric complex then translocates to the nucleus, and binds to IFN-stimulated response elements (ISREs) located in the promoters of ISGs, up-regulating their expression [<xref rid="B60-pathogens-08-00168" ref-type="bibr">60</xref>,<xref rid="B64-pathogens-08-00168" ref-type="bibr">64</xref>]. </p><p>Inflammatory cytokines, such as interleukins (IL)-1A IL-1B and tumor necrosis factor (TNF)-&#x003b1; contribute to the proliferation and migration of different immune cells, such as monocytes, macrophages, neutrophils, and natural killer (NK) cells, to the infected tissue. NK cells have the ability to kill virus-infected cells, are important for the activation of a protective cytotoxic T lymphocyte (CTL) response [<xref rid="B65-pathogens-08-00168" ref-type="bibr">65</xref>], and NK-cell IFN-&#x003b3; production is augmented by T-cell IL-2 production in recall responses [<xref rid="B66-pathogens-08-00168" ref-type="bibr">66</xref>]. Neutrophils and resident alveolar macrophages are also important for virus clearance, due to their ability to destroy infected cells [<xref rid="B67-pathogens-08-00168" ref-type="bibr">67</xref>]. In addition, cytokine signaling improves dendritic cells (DC) maturation, increasing the induction of adaptive immune responses by antigen presentation and co-stimulation [<xref rid="B68-pathogens-08-00168" ref-type="bibr">68</xref>,<xref rid="B69-pathogens-08-00168" ref-type="bibr">69</xref>]. These adaptive immune responses initiated upon innate immune activation are required for protection and viral clearance [<xref rid="B70-pathogens-08-00168" ref-type="bibr">70</xref>].</p><p>NLRP3 is expressed by myeloid cells such as macrophages, monocytes, neutrophils, and dendritic cells [<xref rid="B71-pathogens-08-00168" ref-type="bibr">71</xref>] or by human bronchial epithelial cells [<xref rid="B72-pathogens-08-00168" ref-type="bibr">72</xref>]. Upon stimulation, NLRP3 activates the inflammasome system, activating caspase-1 and leading to pro-inflammatory processes through the processing and activation of proIL-1B, proIL-18, and proIL-33 [<xref rid="B73-pathogens-08-00168" ref-type="bibr">73</xref>]. NLRP3 senses IAV dsRNA [<xref rid="B74-pathogens-08-00168" ref-type="bibr">74</xref>], and PB1-F2 protein [<xref rid="B75-pathogens-08-00168" ref-type="bibr">75</xref>]. Furthermore, protein flux through the viral M2 ion channel activity in the trans-Golgi network activates NLRP3, leading to inflammasome activation [<xref rid="B76-pathogens-08-00168" ref-type="bibr">76</xref>]. In addition to NLRP3 activation, IAV activates the inflammasomes through AIM2, increasing IAV-induced lung injury and mortality [<xref rid="B54-pathogens-08-00168" ref-type="bibr">54</xref>].</p><p>The complement system is an important branch of innate immunity that plays an essential role in the clearance of pathogens. The complement system is triggered by three main pathways, the classical, the lectin, and the alternative pathways [<xref rid="B77-pathogens-08-00168" ref-type="bibr">77</xref>]. The first two pathways are activated with the help of pattern recognition molecules, whereas the alternative pathway is activated spontaneously. Interestingly, it is known that viruses are recognized by the three pathways. In the classical pathway, the C1 complex recognizes antigen-antibody complexes, which are formed on the pathogen surface. C1QBP (Complement C1q Binding Protein) can bind to the globular heads of C1q molecules, activating the classical pathway [<xref rid="B78-pathogens-08-00168" ref-type="bibr">78</xref>]. On the other hand, in the lectin pathway, the mannan-binding lectin (MBL)/ficolin/mannan-binding lectin serin protease (MAP) complex recognizes specific carbohydrates on the pathogen surface. Complexes activated after the classical and lectin pathways, cleave C4 and C2, resulting in the generation of C4bC2a (C3 convertase). In the alternative pathway, spontaneous hydrolysis of native C3 results in the formation of C3b-like C3 that binds factor B and after cleavage by factor D forms the initial C3 convertase [<xref rid="B77-pathogens-08-00168" ref-type="bibr">77</xref>]. The three pathways converge at the cleavage of C3 into C3a and C3b by C3 convertases (C4b, 2a and C3b, Bb). Then, the C3b molecules formed bind covalently to the C3-convertases forming the C5-convertases that cleave C5 into C5a and C5b. CD55 blocks C3 and C5 activation by preventing the formation of new C3 and C5 convertases [<xref rid="B79-pathogens-08-00168" ref-type="bibr">79</xref>]. C5b starts the formation of C5b-9 or the membrane attack complex (MAC). Next, C8 binds to the membrane attached trimer and begins binding and polymerization of C9 that is inserted into the membrane, inducing virolysis [<xref rid="B77-pathogens-08-00168" ref-type="bibr">77</xref>].</p><p>Unregulated complement activation could play a central role in the acute lung injury (ALI) pathology induced by highly pathogenic viruses, including severe acute respiratory syndrome (SARS) coronavirus and avian IAV H5N1, and H7N9 [<xref rid="B80-pathogens-08-00168" ref-type="bibr">80</xref>]. In virus-induced acute lung diseases, high levels of chemotactic, and anaphylatoxic C5a can be generated as a result of excessive complement triggering and causing a &#x0201c;cytokine storm&#x0201d;. Accordingly, the blockade of C5a signaling has been involved in treating the ALI induced by highly pathogenic viruses [<xref rid="B80-pathogens-08-00168" ref-type="bibr">80</xref>]. </p></sec><sec id="sec1dot4-pathogens-08-00168"><title>1.4. Single Nucleotide Polymorphisms (SNPs)</title><p>Currently, particular attention is being paid to single nucleotide polymorphisms (SNPs) that are loci within the genome of an organism in which two or more alleles can exist. SNPs affect a single nucleotide or base pair and they are one of the most frequent types of genetic variations in the genome [<xref rid="B81-pathogens-08-00168" ref-type="bibr">81</xref>,<xref rid="B82-pathogens-08-00168" ref-type="bibr">82</xref>,<xref rid="B83-pathogens-08-00168" ref-type="bibr">83</xref>]. SNPs need to be presented into the population with a frequency equal to or greater than 1% to be considered as polymorphisms. There are multiple types of SNPs, depending on their location that can be in different regions of the genes such as promoters, exons, introns or UTRs (<xref ref-type="fig" rid="pathogens-08-00168-f002">Figure 2</xref>). SNPs in coding regions are classified as synonymous, when a nucleotide substitution does not change the amino acid sequence of the encoded protein, although other effects, such as changes in mRNA structure or folding may account for variation in protein expression. On the other hand, non-synonymous SNPs are divided in missense or nonsense. In the first case, nucleotide substitution results in the change of one amino acid for another, affecting the protein sequence coded by a gene and therefore may lead to its dysfunction. In contrast, nonsense mutations are produced when instead of substituting one amino acid for another, the altered gene contains an early stop codon in the ORF or a stop codon is abrogated, producing an elongated protein. This type of mutations results in shortened or elongated proteins leading typically to nonfunctional proteins. The functional role of SNPs in coding areas of the genome can be easily analyzed by studying the gene products. However, most SNPs fall within non-coding genome regions, therefore, predicting their effects is challenging. For example, SNPs in the promoter regions could affect their activity and regulation producing changes in gene expression levels. SNPs in UTRs or intron regions have been related with an effect in protein translation or the production of splice variants of transcripts, leading to longer or shorter protein sequences, respectively. </p><p>In summary, SNPs may influence gene regulation, the structure and stability of RNA, the expression of RNAs or proteins, the conformation and function of proteins, etc. Thus, the identification of SNPs in genes and the analysis of their effects may lead us to better understand gene function or their impact on human health [<xref rid="B84-pathogens-08-00168" ref-type="bibr">84</xref>]. In fact, SNPs that are or could be important for multiple human pathologies, such as cancer, diabetes, heart disease, schizophrenia, blood-pressure homeostasis, and autoimmune or metabolic diseases, have been identified [<xref rid="B85-pathogens-08-00168" ref-type="bibr">85</xref>,<xref rid="B86-pathogens-08-00168" ref-type="bibr">86</xref>,<xref rid="B87-pathogens-08-00168" ref-type="bibr">87</xref>,<xref rid="B88-pathogens-08-00168" ref-type="bibr">88</xref>,<xref rid="B89-pathogens-08-00168" ref-type="bibr">89</xref>,<xref rid="B90-pathogens-08-00168" ref-type="bibr">90</xref>,<xref rid="B91-pathogens-08-00168" ref-type="bibr">91</xref>]. Moreover, some described SNPs increase the human susceptibility to getting infected by viruses, bacteria or other pathogens [<xref rid="B84-pathogens-08-00168" ref-type="bibr">84</xref>,<xref rid="B86-pathogens-08-00168" ref-type="bibr">86</xref>,<xref rid="B92-pathogens-08-00168" ref-type="bibr">92</xref>,<xref rid="B93-pathogens-08-00168" ref-type="bibr">93</xref>,<xref rid="B94-pathogens-08-00168" ref-type="bibr">94</xref>,<xref rid="B95-pathogens-08-00168" ref-type="bibr">95</xref>,<xref rid="B96-pathogens-08-00168" ref-type="bibr">96</xref>,<xref rid="B97-pathogens-08-00168" ref-type="bibr">97</xref>]. Advanced sequencing and bioinformatics technologies have allowed the identification of a large number of human SNPs whose information is accessible in the databases. Nevertheless, the biological significance and function for most of the SNPs found in the human genome remain unknown. Currently, the scientific community recognizes the importance of this kind of genome variations that can act as biological markers and assist researchers in multiple aspects, such as: (1) Locate genes associated with multiple diseases, (2) anticipate an individual&#x02019;s response to a specific infection, (3) predict population responses to several treatments such as drugs or vaccines, (4) design individualized therapies, (5) identify markers for medical testing, (6) perform pharmacogenetic studies, etc. This review focuses on the role of known SNPs on IAV infection, as well as their impact on the effectiveness of vaccines against IAV.</p></sec></sec><sec id="sec2-pathogens-08-00168"><title>2. SNPs in Host Genes Affecting IAV Disease</title><p>Risk factors, including underlying co-morbidities, age, and pregnancy, affect IAV susceptibility, but do not explain all the conditions under which serious IAV-associated disease can occur, making likely that SNPs in viral and host genes affect IAV susceptibility and the outcome of the disease. In fact, there are some examples of the presence of SNPs in host genes affecting influenza severity (<xref rid="pathogens-08-00168-t001" ref-type="table">Table 1</xref>), which will be discussed in this review. SNPs affecting IAV disease have been found in genes recognizing viral components, in transcription factors important for IFN production and signaling, in ISGs with antiviral activities, and in genes involved in inflammation.</p><p>TLR3 recognizes dsRNA, one of the IAV replication intermediate products, and in turn activates IFN production, leading to an antiviral response. A missense mutation (F303S) of the TLR3 gene was found in one out of three patients developing IAV-associated encephalopathy (IAE), a neurological consequence of severe viral infection [<xref rid="B98-pathogens-08-00168" ref-type="bibr">98</xref>]. Assays in tissue culture cells showed that a TLR3 receptor encoding the missense F303S mutation was impaired in activating the transcription factor NF-&#x003ba;B, and in triggering downstream signaling via the IFN&#x003b2; receptor, indicating that this genetic polymorphism could lead to increased IAV replication [<xref rid="B98-pathogens-08-00168" ref-type="bibr">98</xref>]. In a study of 51 Italian children diagnosed with IAV H1N1 infection, an additional TLR3 SNP (rs5743313, genotype C/T) was identified [<xref rid="B99-pathogens-08-00168" ref-type="bibr">99</xref>]. This TLR3 SNP was found in all the children developing IAV-associated pneumonia (18 cases). However, the SNP was found in significantly less proportion in children with milder disease, suggesting a link between TLR3 and IAV pathogenicity. Furthermore, in a multicenter study involving 275 adult cases of avian H7N9 and pH1N1 IAV, in mainland China and Hong Kong, the TLR3 CC rs5743313 SNP was associated with fatal cases [<xref rid="B100-pathogens-08-00168" ref-type="bibr">100</xref>].</p><p>In addition to IAV, there are other examples of SNPs in TLR3 or TLR3 signaling genes affecting viral infections. For instance, susceptibility to Chikungunya virus (CHIKV) infection is highly increased in human and mouse cells with defective TLR3 molecules [<xref rid="B101-pathogens-08-00168" ref-type="bibr">101</xref>]. Furthermore, <italic>TLR3</italic> SNPs, rs3775292, and rs6552950, leading to unknown functional consequences, were associated with an increased risk of CHIKV disease occurrence [<xref rid="B101-pathogens-08-00168" ref-type="bibr">101</xref>]. Patients with impaired TLR3-mediated responses show an elevated susceptibility to Herpes Simplex-1 Virus (HSV-1)-mediated encephalitis by encoding TLR3-deficient alleles [<xref rid="B102-pathogens-08-00168" ref-type="bibr">102</xref>,<xref rid="B103-pathogens-08-00168" ref-type="bibr">103</xref>], or by encoding deficient TRAF3, TBK1 and TRIF molecules, leading to impaired TLR-3 signaling [<xref rid="B104-pathogens-08-00168" ref-type="bibr">104</xref>,<xref rid="B105-pathogens-08-00168" ref-type="bibr">105</xref>,<xref rid="B106-pathogens-08-00168" ref-type="bibr">106</xref>]. In a Saudi Arabian population, the TLR3 rs78726532 SNP was strongly associated with Hepatitis B (HBV) and Hepatitis C (HCV) virus infections when compared to that in healthy control subjects [<xref rid="B107-pathogens-08-00168" ref-type="bibr">107</xref>,<xref rid="B108-pathogens-08-00168" ref-type="bibr">108</xref>]. The TLR3 rs5743314 C allele was also associated with HCV-related liver disease progression (cirrhosis and hepatocellular carcinoma) [<xref rid="B107-pathogens-08-00168" ref-type="bibr">107</xref>]. However, the functional effects of these SNPs seem to be unknown.</p><p>RIG-I detects dsRNA and 5&#x02032;-triphosphates of the negative ssRNA IAV genome, leading to innate immune responses activation [<xref rid="B52-pathogens-08-00168" ref-type="bibr">52</xref>]. A Caucasian male patient with severe IAV H1N1 infection during the 2009 swine flu pandemic showed two heterozygous variants (one in each chromosome): p.R71H (SNP rs72710678) and p.P885S (SNP rs138425677), located, respectively, in the caspase activation and recruitment domain (CARD) and RNA binding domains of RIG-I [<xref rid="B109-pathogens-08-00168" ref-type="bibr">109</xref>]. These variants significantly decreased the recognition function of RIG-I, and therefore, patient cells proved impaired antiviral responses to RIG-I ligands and elevated proinflammatory responses to IAV, providing evidence for dysregulation of the innate immune response and increased immunopathology [<xref rid="B109-pathogens-08-00168" ref-type="bibr">109</xref>]. These results suggest that these RIG-I polymorphisms may have contributed to severe IAV outcome in this patient and reinforce that RIG-I variants should be evaluated in future studies of host factors affecting ssRNA virus infections.</p><p>IRF-7 is a transcription factor that increases interferon (IFN) production in response to viruses [<xref rid="B110-pathogens-08-00168" ref-type="bibr">110</xref>,<xref rid="B111-pathogens-08-00168" ref-type="bibr">111</xref>,<xref rid="B112-pathogens-08-00168" ref-type="bibr">112</xref>]. A patient suffering from an unusual life-threatening disease after pH1N1 infection encodes homozygous null mutations in the IRF-7 factor. Both IRF-7 alleles from this patient encode mutations c.1228T&#x0003e;G/T (F410V) and c.1261C&#x0003e;T/C (Q421X), which are mutations decreasing the ability of IRF-7 to induce the transcription of IFN genes after IAV infections [<xref rid="B113-pathogens-08-00168" ref-type="bibr">113</xref>]. These findings suggest that IRF-7-dependent production of type I and III IFNs is required for controlling IAV infections in humans. The rare allele A of two IRF-7 SNPs, rs12272434 and rs12290989, both located at exon/intron boundaries, were significantly associated with impaired levels of IFN&#x003b1; production by human plasmacytoid dendritic cells (pDCs) in response to human immunodeficiency virus 1 (HIV-1) infection [<xref rid="B114-pathogens-08-00168" ref-type="bibr">114</xref>]. Therefore, these polymorphisms may affect the ability of human subjects to control HIV-1 infections, reinforcing the role of IRF-7 in controlling viral infections. However, the effect of these SNPs should be further studied. </p><p>IRF-9 is a transcription factor essential for IFN signaling and the transcriptional induction of ISGs [<xref rid="B60-pathogens-08-00168" ref-type="bibr">60</xref>]. STAT1 and STAT2, when phosphorylated, associate with IRF-9 to form a heterotrimeric ISG factor 3 (ISGF3) complex [<xref rid="B60-pathogens-08-00168" ref-type="bibr">60</xref>], which translocates to the nucleus, and binds ISREs present in the promoters of ISGs, up-regulating their transcription [<xref rid="B60-pathogens-08-00168" ref-type="bibr">60</xref>,<xref rid="B64-pathogens-08-00168" ref-type="bibr">64</xref>]. A homozygous, loss-of-function mutation in IRF-9 was described in a child born to first-cousin Algerian parents and living in France affected by a severe pulmonary influenza infection [<xref rid="B115-pathogens-08-00168" ref-type="bibr">115</xref>]. In particular, the homozygous mutation (c.991G&#x0003e;A) occurred in the final nucleotide of exon 7 and disrupted the essential splice site at the boundary of exon 7 and intron 7, leading to deleted IRF-9 proteins. The consequence of this mutation was an impaired activation of IRF-9, and therefore, an impaired transcription of ISGs, many of which show antiviral activities [<xref rid="B115-pathogens-08-00168" ref-type="bibr">115</xref>]. Similarly, a family in which several members showed a surprising susceptibility to infection by different viruses, including IAV, also showed to be IRF9 deficient [<xref rid="B116-pathogens-08-00168" ref-type="bibr">116</xref>]. The index patient, a boy with 10 years born at term from healthy consanguineous parents (first cousins of Portuguese origin and residing in Venezuela) encoded a homozygous splicing mutation in the IRF9 gene. The mutation, c.577+1G&#x0003e;T, was located in the donor splice site of introns 5 and 6, leading to transcripts lacking exon 5. IRF9 protein expression was undetectable in cells transfected with the c.577+1G&#x0003e;T IRF9 construct, suggesting that either the protein was quickly degraded or the mRNA was not translated. Again, IRF9-deficient cells showed a profound defect in inducing the expression of multiple ISGs [<xref rid="B116-pathogens-08-00168" ref-type="bibr">116</xref>]. Collectively, these findings show that human IRF9- and ISGF3-dependent type I and III IFN responsive pathways are essential for controlling viral infections, including IAV.</p><p>The antiviral protein IFITM3 is an ISG which abrogates the release of IAV content from late endosomes into the cytoplasm [<xref rid="B59-pathogens-08-00168" ref-type="bibr">59</xref>]. In addition, IFITM3 promotes the survival of mouse lung-resident CD8+ T cells following IAV challenge, which may help clear the infection [<xref rid="B117-pathogens-08-00168" ref-type="bibr">117</xref>]. Furthermore, mice in which the expression of IFITM3 is abolished, showed severe disease after IAV infection, compared to parental mice [<xref rid="B118-pathogens-08-00168" ref-type="bibr">118</xref>]. One of the clearest associations of SNPs in genes affecting influenza severity is located in the ISG IFITM3. The human IFITM3 gene is encoded by two exons and is predicted to encode two splice variants that differ in the first amino-terminal 21 amino acids. Different studies have described the effect of IFITM3 SNPs in influenza disease severity. Northern European patients infected with IAV pH1N1 2009 virus requiring hospitalization showed over-representation of the SNP rs12252 in the IFITM3 gene, in which the majority T allele is replaced for a minority C allele [<xref rid="B118-pathogens-08-00168" ref-type="bibr">118</xref>]. This leads to an alteration of the first splice acceptor site, originating an IFITM3 protein lacking the first 21 amino acids (N&#x00394;21) due to the protein starting from an alternative start codon. According to these results suggesting that this SNP could affect influenza disease, the minority (CC) variant rendered homozygous cells more susceptible to IAV infection, and this susceptibility correlated with decreased levels of IFITM3 protein expression in comparison to the majority (TT) variant cells [<xref rid="B118-pathogens-08-00168" ref-type="bibr">118</xref>]. Furthermore, cells expressing the N&#x00394;21 protein showed an impaired ability to restrict viral replication when compared to wild-type IFITM3 cells [<xref rid="B118-pathogens-08-00168" ref-type="bibr">118</xref>]. This data is consistent with previous results which show that the amino-terminal 21 amino acids of IFITM3 are relevant for attenuating vesicular stomatitis virus (VSV) replication in vitro [<xref rid="B119-pathogens-08-00168" ref-type="bibr">119</xref>]. Moreover, the CC genotype was found in 25% of Chinese patients showing mild disease after pH1N1 virus infection compared to 69% in patients developing a severe pH1N1 virus infection. In addition, the CC genotype was estimated to confer a six-fold increased risk for severe infection than the CT and TT genotypes [<xref rid="B120-pathogens-08-00168" ref-type="bibr">120</xref>], reinforcing the idea that IFITM3 is a factor affecting human IAV disease [<xref rid="B121-pathogens-08-00168" ref-type="bibr">121</xref>]. In another study, over-representation of the IFITM3 CC genotype was detected among fatal cases of Chinese patients infected with IAV pH1N1 and H7N9 viruses [<xref rid="B100-pathogens-08-00168" ref-type="bibr">100</xref>], and in a more general study, including twelve studies published before February 2018 with more than 16,000 subjects, revealed increased risk of severe influenza in both the East Asian and White populations in the subjects encoding the IFITM3 CC genotype [<xref rid="B122-pathogens-08-00168" ref-type="bibr">122</xref>].</p><p>Another important SNP (rs34481144) associated with risk of severe influenza in humans from the United States (US) infected with seasonal IAVs is located in the 5&#x02032;-UTR of the IFITM3 gene [<xref rid="B123-pathogens-08-00168" ref-type="bibr">123</xref>,<xref rid="B124-pathogens-08-00168" ref-type="bibr">124</xref>]. This SNP affected IFITM3 expression being the risk allele associated with lower mRNA expression. The mechanism for this lower mRNA expression involves the decreased IRF-3 binding and increased binding of the transcriptional repressor CCCTC-binding factor (CTCF) in promoter-binding assays for the risk allele [<xref rid="B123-pathogens-08-00168" ref-type="bibr">123</xref>]. Moreover, the risk allele disrupted a CpG site that becomes differentially methylated in CD8+ T cell subsets, leading to less CD8+ T cells in the airways during natural influenza infection in the carriers of the risk allele, and suggesting that a critical role for IFITM3 may be to promote immune cell persistence at mucosal sites [<xref rid="B123-pathogens-08-00168" ref-type="bibr">123</xref>]. </p><p>Interleukins 1A and 1B (IL-1A and IL-1B, respectively) are inflammatory cytokines that play critical roles in recruiting immune and inflammatory cells and developing adaptive immune responses. Furthermore, accumulating evidence suggests that both cytokines play central roles in innate immunity against viral infections [<xref rid="B125-pathogens-08-00168" ref-type="bibr">125</xref>]. The frequencies of SNP (allele C) located 31 base pairs upstream from the transcription start site (rs1143627), on the IL-1B promoter were associated with increased risk of influenza disease in Chinese subjects [<xref rid="B126-pathogens-08-00168" ref-type="bibr">126</xref>]. This nucleotide change is localized in a TATA-box motif of IL-1B and modulates the transcription activity of IL-1B by binding to multiple transcription factors [<xref rid="B127-pathogens-08-00168" ref-type="bibr">127</xref>]. The allele T of rs1143627 enhanced IL-1B protein expression, as indicated by several reports [<xref rid="B128-pathogens-08-00168" ref-type="bibr">128</xref>]. People carrying allele T showed a higher IL-1B expression, which could lead to increased IFN&#x003b3; production, which promotes virus clearance [<xref rid="B129-pathogens-08-00168" ref-type="bibr">129</xref>]. In contrast, expression of IL-1B may be decreased in individuals who carry allele C, leading to a weaker immune response during viral infection. In addition, a T allele in IL-1A gene (SNP rs17561) increased the risk of IAV pH1N1 susceptibility, as observed in Chinese subjects [<xref rid="B126-pathogens-08-00168" ref-type="bibr">126</xref>]. The SNP rs17561 introduces a nonsynonymous mutation (A114S) in IL-1A protein, suggesting that this genetic variant may lead to a functional variation in host susceptibility to pH1N1. Nevertheless, the molecular mechanism needs to be evaluated and the real risk of these alleles should be analyzed in larger populations.</p><p>TNF-&#x003b1; is a pro-inflammatory cytokine which orchestrates the host&#x000b4;s defense. A minor allele (A) at position -238 of TNF (SNP rs361525) was more frequent in Greek patients infected with pH1N1 virus compared to control subjects [<xref rid="B130-pathogens-08-00168" ref-type="bibr">130</xref>], and developing pneumonia was more uncommon in Greek and Mexican subjects with no copies of the minor allele compared to subjects with at least one copy of the minor allele [<xref rid="B130-pathogens-08-00168" ref-type="bibr">130</xref>,<xref rid="B131-pathogens-08-00168" ref-type="bibr">131</xref>], leading to the hypothesis that this SNP allele could be linked with an elevated susceptibility to infection with the pH1N1 virus [<xref rid="B124-pathogens-08-00168" ref-type="bibr">124</xref>,<xref rid="B130-pathogens-08-00168" ref-type="bibr">130</xref>]. Decreased TNF-&#x003b1; expression was observed in subjects encoding the minor allele at position -238 [<xref rid="B92-pathogens-08-00168" ref-type="bibr">92</xref>]. This may explain how SNPs leading to lower production of TNF-&#x003b1; may predispose to more severe clinical symptoms following IAV infections. However, the TNF-&#x003b1; rs 1800629 minor A allele, associated with higher levels of TNF-&#x003b1; expression, was associated with susceptibility to Japanese Encephalitis virus infection in an Indian population [<xref rid="B132-pathogens-08-00168" ref-type="bibr">132</xref>]. The TNF-&#x003b1; rs 1800629 minor A allele was a risk factor to develop liver cirrhosis and hepatocellular carcinoma following HBV infection in a Han Chinese population [<xref rid="B133-pathogens-08-00168" ref-type="bibr">133</xref>], suggesting that the protective or deleterious roles of TNF-&#x003b1; expression may vary depending on the infecting virus. </p><p>Chemokine receptor 5 (CCR5) is expressed mainly on macrophages, T cells, and dendritic cells. CCR5 mediates leukocyte chemotaxis in response to its ligands, including MIP-1a, MIP-1b, and RANTES. It can help direct multiple immune cell subsets, including regulatory T cells or Th17 cells to sites of infection, supporting the antiviral immune response. Evidence in humans support that homozygosity for the CCR5-&#x00394;32 allele, a naturally occurring polymorphism of CCR5 encoding a 32-bp deletion, prevents its expression on the cell surface, and is linked with an elevated susceptibility to West Nile virus (WNV) [<xref rid="B134-pathogens-08-00168" ref-type="bibr">134</xref>] and with increased severity of illness among patients infected with pH1N1 [<xref rid="B135-pathogens-08-00168" ref-type="bibr">135</xref>], although this evidence is modest due to the limited number of subjects analyzed. In contrast, homozygous carriers of the &#x00394;32 mutation are resistant to HIV-1 infection because this molecule, absent in the cell surface in subjects encoding the deletion, is a molecule normally used by HIV-1 to enter CD4+ T cells [<xref rid="B136-pathogens-08-00168" ref-type="bibr">136</xref>].</p><p>CD55 is an important complement regulatory protein which blocks C3 and C5 activation by preventing the formation of new C3 and C5 convertases, two proteases involved in inflammation and complement activation. Consequently, CD55 protects cells from complement attack and decreases amplification of the complement cascade [<xref rid="B79-pathogens-08-00168" ref-type="bibr">79</xref>]. The CD55 SNP (rs2564978, genotype T/T) was significantly associated with severe IAV infection in Chinese patients infected with pH1N1 2009 virus [<xref rid="B137-pathogens-08-00168" ref-type="bibr">137</xref>] and was associated with increased death risk in Greek patients [<xref rid="B138-pathogens-08-00168" ref-type="bibr">138</xref>]. The rs2564978 SNP of CD55 is located in the minimal promoter region [<xref rid="B139-pathogens-08-00168" ref-type="bibr">139</xref>] and individuals with this genotype showed significantly lower levels of CD55 expression in comparison to those with the more frequent allele [<xref rid="B137-pathogens-08-00168" ref-type="bibr">137</xref>]. Therefore, patients who carry the T/T genotype may have more robust complement activation during IAV infection, resulting in enhanced inflammation and disease severity [<xref rid="B47-pathogens-08-00168" ref-type="bibr">47</xref>,<xref rid="B79-pathogens-08-00168" ref-type="bibr">79</xref>]. According to these results, the polymorphism rs2564978 in gene CD55 was linked to disease severity in adult Chinese cases of avian (H7N9) and human pH1N1 IAV in another study [<xref rid="B100-pathogens-08-00168" ref-type="bibr">100</xref>]. However, these findings need to be confirmed in bigger cohorts. </p><p>C1QBP can bind to the globular heads of C1q molecules, activating the classical pathway of complement [<xref rid="B78-pathogens-08-00168" ref-type="bibr">78</xref>]. An increased risk of severe disease after IAV infection was found in patients homozygous for the minor allele of the SNP rs3786054 in European and Mexican populations [<xref rid="B138-pathogens-08-00168" ref-type="bibr">138</xref>,<xref rid="B140-pathogens-08-00168" ref-type="bibr">140</xref>]. However, the effect of this SNPs on gene expression and function is undescribed.</p><p>Soluble pattern-recognition molecules, forming part of the innate immune system, can neutralize IAV infection. Particularly, the serum mannose-binding lectin (MBL), several secreted human C-type lectins of the collectin family, collectin 11, and the pulmonary surfactant proteins (SP) &#x02013;A1, &#x02013;A2, and &#x02013;D (SFTPA1, SFTPA2, and SFTPD, respectively), may neutralize IAV infectivity in vitro [<xref rid="B141-pathogens-08-00168" ref-type="bibr">141</xref>]. Mice lacking SP-A or SP-D were more susceptible to IAV infection, indicating that SPs exert relevant roles against IAV infection [<xref rid="B142-pathogens-08-00168" ref-type="bibr">142</xref>,<xref rid="B143-pathogens-08-00168" ref-type="bibr">143</xref>,<xref rid="B144-pathogens-08-00168" ref-type="bibr">144</xref>]. Two frequent SP-A2 (SFTPA2) missense alleles (rs1965708-C, leading to the mutation Q223K and rs1059046-A, leading to the mutation T9N) were associated with acute respiratory failure, mechanical ventilation, and acute respiratory distress syndrome after infection with pH1N1 2009 virus in a Spanish population [<xref rid="B145-pathogens-08-00168" ref-type="bibr">145</xref>]. </p><p>In addition to C-type lectins, S-type lectins have been described, such as galectins, which recognize galactose-containing oligosaccharides present in the cellular plasma membranes and in viruses, such as IAV. Importantly, intranasal treatment of galectin-1 enhanced survival of mice infected with IAV by reducing viral load, apoptosis, and inflammation in the lung [<xref rid="B146-pathogens-08-00168" ref-type="bibr">146</xref>]. Moreover, galectin-1 knockout mice showed increased susceptibility to influenza virus infection than wild-type mice [<xref rid="B146-pathogens-08-00168" ref-type="bibr">146</xref>]. To study human genetic susceptibility to avian IAV H7N9 infection, a genome-wide association study involving 106 heavily-exposed healthy poultry Chinese workers and 102 IAV H7N9 patients was performed [<xref rid="B147-pathogens-08-00168" ref-type="bibr">147</xref>]. Functional variants of galectin-1 gene, including rs4820294 and rs13057866, causing increased expression levels of galectin-1 expression, may confer more protection from IAV H7N9 infection to the carriers of these variants [<xref rid="B147-pathogens-08-00168" ref-type="bibr">147</xref>]. </p><p>The cleavage of the IAV HA by host proteases is critical for viral infectivity. TMPRSS2 is a type II transmembrane serine protease family member, which was shown to activate HA proteins of multiple human IAVs in tissue culture cells. Furthermore, deletion of Tmprss2 in mice impairs the spread of H1N1 influenza viruses, including the pH1N1 2009 swine IAV [<xref rid="B148-pathogens-08-00168" ref-type="bibr">148</xref>]. In addition, bodyweight loss and survival after H3N2 IAV infection were less severe in Tmprss2 mutant mice compared to wild type mice [<xref rid="B148-pathogens-08-00168" ref-type="bibr">148</xref>]. The genetic predisposition to severe pH1N1 2009 influenza virus was evaluated in Chinese human subjects, finding that the GG genotype of rs2070788, leading to increased expression of TMPRSS2, was a risk variant to severe pH1N1 influenza [<xref rid="B149-pathogens-08-00168" ref-type="bibr">149</xref>]. Furthermore, rs2070788 and rs383510, both of them associated with increased gene expression, were significantly associated with the susceptibility to IAV H7N9 [<xref rid="B149-pathogens-08-00168" ref-type="bibr">149</xref>]. </p></sec><sec id="sec3-pathogens-08-00168"><title>3. SNPs in Genes that Influence the IAV Vaccine Response</title><p>Currently, IAV vaccines are the main strategy to prevent IAV infection, though their effectiveness is suboptimal in many cases. Notably, the efficacy of vaccines against IAV infections can fluctuate and there is a significant immune response variability across the population. Factors such as previous exposure to IAV infections or vaccines, age, and the closeness of the match between the vaccine and circulating strains are important to explain differences in vaccine effectiveness between seasons and group populations [<xref rid="B44-pathogens-08-00168" ref-type="bibr">44</xref>,<xref rid="B46-pathogens-08-00168" ref-type="bibr">46</xref>,<xref rid="B150-pathogens-08-00168" ref-type="bibr">150</xref>,<xref rid="B151-pathogens-08-00168" ref-type="bibr">151</xref>,<xref rid="B152-pathogens-08-00168" ref-type="bibr">152</xref>]. However, multiple reports have demonstrated that the host genetic background and polymorphisms on key immune response genes modulate the immune response to infection or vaccination [<xref rid="B153-pathogens-08-00168" ref-type="bibr">153</xref>,<xref rid="B154-pathogens-08-00168" ref-type="bibr">154</xref>,<xref rid="B155-pathogens-08-00168" ref-type="bibr">155</xref>,<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>,<xref rid="B157-pathogens-08-00168" ref-type="bibr">157</xref>,<xref rid="B158-pathogens-08-00168" ref-type="bibr">158</xref>,<xref rid="B159-pathogens-08-00168" ref-type="bibr">159</xref>,<xref rid="B160-pathogens-08-00168" ref-type="bibr">160</xref>]. Therefore, new insights into IAV-host interaction and immune response modulating factors could allow us to design better vaccination strategies. </p><p>SNPs may modify the humoral immune response after IAV vaccination. Therefore, their impact on the immune responses induced after IAV vaccination are being analyzed [<xref rid="B153-pathogens-08-00168" ref-type="bibr">153</xref>,<xref rid="B154-pathogens-08-00168" ref-type="bibr">154</xref>,<xref rid="B155-pathogens-08-00168" ref-type="bibr">155</xref>,<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]. The major histocompatibility complex (MHC) is localized in chromosome 6 of the human genome, it includes multiple genes and exhibits considerable diversity between populations. Moreover, in this genomic region, there is a higher presence of SNPs than in other sections of the genome. MHC class I and class II molecules have an essential role in the adaptive immune system in response to infections. Both classes of proteins bind peptide fragments derived from pathogens to be presented on the cell surface for recognition by appropriate T cells [<xref rid="B97-pathogens-08-00168" ref-type="bibr">97</xref>,<xref rid="B161-pathogens-08-00168" ref-type="bibr">161</xref>,<xref rid="B162-pathogens-08-00168" ref-type="bibr">162</xref>]. In those genes, the human leukocyte antigens (HLA) class I and II are important because of their role in the immune system. Gelder et al. studied whether HLA class II polymorphisms modulate anti-IAV antibody responses to vaccination in a United Kingdom population [<xref rid="B154-pathogens-08-00168" ref-type="bibr">154</xref>]. For that, a cohort of HLA-typed donors at risk was investigated, and hemagglutination-inhibition (HAI) titers were evaluated before and 28 days after the administration of seasonal trivalent influenza vaccine. A correlation between HLA class II alleles and IAV HAI titers in the influenza risk group was found. Moreover, a positive association between non-responsiveness to influenza vaccine and HLA-DRB1*07 and a negative association with HLA-DRB1*13 and HLA-DQB1*0603-9/14 [<xref rid="B154-pathogens-08-00168" ref-type="bibr">154</xref>] was reported, suggesting that polymorphisms in HLA class II molecules affect antibody responses to IAV vaccination. These findings are important because they could potentially identify individuals who may not be protected by current vaccination approaches. </p><p>In another study, Poland et al. analyzed the immunogenetic relationships between HLA, cytokine and cytokine receptor gene polymorphisms in the induction of antibodies in response to inactivated seasonal vaccines [<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]. Authors did not find statistically significant associations between HLA class II alleles and IAV HAI titers. However, they established a positive association of some HLA class I alleles and IAV H1N1 HAI titers, including HLA- A*1101, A*6801, B*3503, B*1401, and C*0802. In contrast, they did not find associations between the HLA-A, B or C alleles and HAI antibody titers for IAV H3N2. In addition, when authors evaluated a panel of 586 cytokine and cytokine receptor SNPs, they identified several significant associations between SNPs, in regulatory or coding regions of cytokine (IL-6, IL-12B) or cytokine receptor (IL-1R, IL-10RB, TNFRSF1A) genes and variations in HAI antibody titers for IAV H1N1 [<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>] (<xref rid="pathogens-08-00168-t002" ref-type="table">Table 2</xref>). Notably, SNPs from three genes, IL-6 (rs1800796), IL-12B (rs3212227) and IL-1R1 (rs3732131) revealed links with IAV H1N1-induced antibody responses in an allele dose-related way. The presence of SNP allele C or G in the IL-12B or IL-1R1genes, respectively resulted in reduced HAI titers. However, high HAI titers in the presence of minor SNP allele G in the IL-6 gene were observed [<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]. SNPs associations between cytokine or cytokine receptor genes and IAV H3N2 HAI titers were also identified (<xref rid="pathogens-08-00168-t002" ref-type="table">Table 2</xref>). For example, a variant GA for non-synonymous SNPs within the IL-12 receptor gene (rs2307153; D465G) and TNF receptor 2 gene (rs5746026; K232E) displayed associations with lower HAI titers, while a minor allele T variant (rs12722605) located in the 3&#x02032; region of the IL-2 receptor gene was related with high antibody titers (<xref rid="pathogens-08-00168-t002" ref-type="table">Table 2</xref>). These data suggest that host SNPs affect responses to influenza vaccine.</p><p>Mannose-binding lectin 2 (MBL-2) is a protein that binds N-acetylglucosamine, mannose, and fucose on different microorganisms and activates the lectin complement pathway [<xref rid="B163-pathogens-08-00168" ref-type="bibr">163</xref>,<xref rid="B164-pathogens-08-00168" ref-type="bibr">164</xref>]. Tang et al. studied the presence of SNPs in subjects who received an inactivated influenza vaccine. For that, authors classified the vaccine recipients in poor, normal or adverse responders. They observed that the G to A SNP in the codon 54 allele (rs1800450) in MBL-2 was associated with a decreased risk for the development of adverse or poor responses (<xref rid="pathogens-08-00168-t002" ref-type="table">Table 2</xref>) [<xref rid="B165-pathogens-08-00168" ref-type="bibr">165</xref>]. In addition, they did not find a significant association between responses and either TNF-&#x003b1; or IL-10 promoter SNPs among the 3 response groups [<xref rid="B165-pathogens-08-00168" ref-type="bibr">165</xref>]. </p><p>Other SNPs that are not related with immune responses have been also linked to vaccine effectiveness. Egli et al. revealed that the presence of the T/G or G/G genotype (rs8099917, minor-allele) in IL-28B (IFN&#x003bb;3), a type III IFN, was linked with increased seroconversion in recipients of an inactivated influenza vaccine (<xref rid="pathogens-08-00168-t002" ref-type="table">Table 2</xref>) [<xref rid="B153-pathogens-08-00168" ref-type="bibr">153</xref>]. Moreover, IAV-stimulated B- and T-cells from the minor-allele carriers exhibited increased HLA-DR and IL-4 expression, respectively. In addition, the expression of IL-28B, but not IL-28A or IL-29, mRNAs was significantly reduced in the rs8099917, minor-allele carriers. Authors also reported that the IL-28B rs8099917 polymorphism affected humoral responses to the IAV vaccine, and had a strong outcome on cellular immune responses by modulating the Th1/Th2 cytokine response [<xref rid="B153-pathogens-08-00168" ref-type="bibr">153</xref>]. These findings are important because they will help to predict which individuals could not be protected by present vaccines and they can also be used to design personalized vaccine strategies to optimize the immune reaction.</p></sec><sec sec-type="conclusions" id="sec4-pathogens-08-00168"><title>4. Conclusions</title><p>The sequencing of the human genome together with the development of novel bioinformatic tools have made possible the identification of multiple SNPs. More information is available for the scientific community in the databases. In addition, the identification and study of the human genome variability has opened the opportunity to investigate their association with the risk of developing multiple human diseases facilitating their diagnosis or the susceptibility to infections caused by viruses or other pathogens. Moreover, the knowledge and analysis of genomic variability will be a valuable tool to predict the outcome of prophylactic or therapeutic interventions, including vaccines and drugs. The analysis of human SNPs and their association with IAV infections or vaccination outcomes have just begun. However, current research and data reflect the importance to obtain a better understanding of these relations and the mechanisms underlying the effect of SNPs in the human immune system. In the future, this knowledge could be used to better understand host factors affecting viral replication and disease severity and to develop new and more effective therapeutic strategies against viral infections. </p></sec></body><back><ack><title>Acknowledgments</title><p>We apologize for those publications we could not refer due to space limitations.</p></ack><notes><title>Author Contributions</title><p>A.N. and M.L.D. conceptualized and wrote the manuscript. </p></notes><notes><title>Funding</title><p>This work was supported with funds from Comunidad de Madrid, Spain, reference 2017-T1/BMD-5155 and the Spanish Ministry of Science, Innovation and Universities (RTI-2018-094213-A-I00) to M.L.D and the &#x0201c;Ramon y Cajal&#x0201d; Fellowship RYC-2017 from Spanish Ministry of Economy, Industry and Competitiveness to A.N.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. </p></notes><ref-list><title>References</title><ref id="B1-pathogens-08-00168"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heldt</surname><given-names>F.S.</given-names></name><name><surname>Frensing</surname><given-names>T.</given-names></name><name><surname>Reichl</surname><given-names>U.</given-names></name></person-group><article-title>Modeling the intracellular dynamics of influenza virus replication to understand the control of viral RNA synthesis</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>7806</fpage><lpage>7817</lpage><pub-id pub-id-type="doi">10.1128/JVI.00080-12</pub-id><?supplied-pmid 22593159?><pub-id pub-id-type="pmid">22593159</pub-id></element-citation></ref><ref id="B2-pathogens-08-00168"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Peersen</surname><given-names>O.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name></person-group><article-title>Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>560</elocation-id><pub-id pub-id-type="doi">10.3390/v10100560</pub-id><?supplied-pmid 30326610?><pub-id pub-id-type="pmid">30326610</pub-id></element-citation></ref><ref id="B3-pathogens-08-00168"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arranz</surname><given-names>R.</given-names></name><name><surname>Coloma</surname><given-names>R.</given-names></name><name><surname>Chichon</surname><given-names>F.J.</given-names></name><name><surname>Conesa</surname><given-names>J.J.</given-names></name><name><surname>Carrascosa</surname><given-names>J.L.</given-names></name><name><surname>Valpuesta</surname><given-names>J.M.</given-names></name><name><surname>Ortin</surname><given-names>J.</given-names></name><name><surname>Martin-Benito</surname><given-names>J.</given-names></name></person-group><article-title>The structure of native influenza virion ribonucleoproteins</article-title><source>Science</source><year>2012</year><volume>338</volume><fpage>1634</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.1126/science.1228172</pub-id><pub-id pub-id-type="pmid">23180776</pub-id></element-citation></ref><ref id="B4-pathogens-08-00168"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflug</surname><given-names>A.</given-names></name><name><surname>Guilligay</surname><given-names>D.</given-names></name><name><surname>Reich</surname><given-names>S.</given-names></name><name><surname>Cusack</surname><given-names>S.</given-names></name></person-group><article-title>Structure of influenza A polymerase bound to the viral RNA promoter</article-title><source>Nature</source><year>2014</year><volume>516</volume><fpage>355</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/nature14008</pub-id><?supplied-pmid 25409142?><pub-id pub-id-type="pmid">25409142</pub-id></element-citation></ref><ref id="B5-pathogens-08-00168"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflug</surname><given-names>A.</given-names></name><name><surname>Lukarska</surname><given-names>M.</given-names></name><name><surname>Resa-Infante</surname><given-names>P.</given-names></name><name><surname>Reich</surname><given-names>S.</given-names></name><name><surname>Cusack</surname><given-names>S.</given-names></name></person-group><article-title>Structural insights into RNA synthesis by the influenza virus transcription-replication machine</article-title><source>Virus Res.</source><year>2017</year><volume>234</volume><fpage>103</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2017.01.013</pub-id><?supplied-pmid 28115197?><pub-id pub-id-type="pmid">28115197</pub-id></element-citation></ref><ref id="B6-pathogens-08-00168"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resa-Infante</surname><given-names>P.</given-names></name><name><surname>Jorba</surname><given-names>N.</given-names></name><name><surname>Coloma</surname><given-names>R.</given-names></name><name><surname>Ortin</surname><given-names>J.</given-names></name></person-group><article-title>The influenza virus RNA synthesis machine: Advances in its structure and function</article-title><source>RNA Biol.</source><year>2011</year><volume>8</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.4161/rna.8.2.14513</pub-id><pub-id pub-id-type="pmid">21358279</pub-id></element-citation></ref><ref id="B7-pathogens-08-00168"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>S.F.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group><article-title>Downregulating viral gene expression: Codon usage bias manipulation for the generation of novel influenza A virus vaccines</article-title><source>Future Virol.</source><year>2015</year><volume>10</volume><fpage>715</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.2217/fvl.15.31</pub-id><pub-id pub-id-type="pmid">26213563</pub-id></element-citation></ref><ref id="B8-pathogens-08-00168"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>H.M.</given-names></name><name><surname>Foeglein</surname><given-names>A.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Dalton</surname><given-names>R.M.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Howard</surname><given-names>W.</given-names></name><name><surname>Anderson</surname><given-names>E.C.</given-names></name><name><surname>Barclay</surname><given-names>W.S.</given-names></name><name><surname>Digard</surname><given-names>P.</given-names></name></person-group><article-title>A complicated message: Identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>8021</fpage><lpage>8031</lpage><pub-id pub-id-type="doi">10.1128/JVI.00826-09</pub-id><pub-id pub-id-type="pmid">19494001</pub-id></element-citation></ref><ref id="B9-pathogens-08-00168"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagger</surname><given-names>B.W.</given-names></name><name><surname>Wise</surname><given-names>H.M.</given-names></name><name><surname>Kash</surname><given-names>J.C.</given-names></name><name><surname>Walters</surname><given-names>K.A.</given-names></name><name><surname>Wills</surname><given-names>N.M.</given-names></name><name><surname>Xiao</surname><given-names>Y.L.</given-names></name><name><surname>Dunfee</surname><given-names>R.L.</given-names></name><name><surname>Schwartzman</surname><given-names>L.M.</given-names></name><name><surname>Ozinsky</surname><given-names>A.</given-names></name><name><surname>Bell</surname><given-names>G.L.</given-names></name><etal/></person-group><article-title>An overlapping protein-coding region in influenza A virus segment 3 modulates the host response</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1126/science.1222213</pub-id><pub-id pub-id-type="pmid">22745253</pub-id></element-citation></ref><ref id="B10-pathogens-08-00168"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvier</surname><given-names>N.M.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>The biology of influenza viruses</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>D49</fpage><lpage>D53</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.039</pub-id><pub-id pub-id-type="pmid">19230160</pub-id></element-citation></ref><ref id="B11-pathogens-08-00168"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrd-Leotis</surname><given-names>L.</given-names></name><name><surname>Cummings</surname><given-names>R.D.</given-names></name><name><surname>Steinhauer</surname><given-names>D.A.</given-names></name></person-group><article-title>The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>1541</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18071541</pub-id><?supplied-pmid 28714909?><pub-id pub-id-type="pmid">28714909</pub-id></element-citation></ref><ref id="B12-pathogens-08-00168"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De</surname><given-names>A.</given-names></name></person-group><article-title>Molecular evolution of hemagglutinin gene of Influenza A virus</article-title><source>Front. Biosci.</source><year>2018</year><volume>10</volume><fpage>101</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.2741/s502</pub-id></element-citation></ref><ref id="B13-pathogens-08-00168"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>M.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group><article-title>The role of receptor binding specificity in interspecies transmission of influenza viruses</article-title><source>Curr. Opin. Virol.</source><year>2012</year><volume>2</volume><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2012.03.003</pub-id><?supplied-pmid 22445963?><pub-id pub-id-type="pmid">22445963</pub-id></element-citation></ref><ref id="B14-pathogens-08-00168"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAuley</surname><given-names>J.L.</given-names></name><name><surname>Gilbertson</surname><given-names>B.P.</given-names></name><name><surname>Trifkovic</surname><given-names>S.</given-names></name><name><surname>Brown</surname><given-names>L.E.</given-names></name><name><surname>McKimm-Breschkin</surname><given-names>J.L.</given-names></name></person-group><article-title>Influenza Virus Neuraminidase Structure and Functions</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.00039</pub-id><?supplied-pmid 30761095?><pub-id pub-id-type="pmid">30761095</pub-id></element-citation></ref><ref id="B15-pathogens-08-00168"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaymard</surname><given-names>A.</given-names></name><name><surname>Le Briand</surname><given-names>N.</given-names></name><name><surname>Frobert</surname><given-names>E.</given-names></name><name><surname>Lina</surname><given-names>B.</given-names></name><name><surname>Escuret</surname><given-names>V.</given-names></name></person-group><article-title>Functional balance between neuraminidase and haemagglutinin in influenza viruses</article-title><source>Clin. Microbiol. Infect.</source><year>2016</year><volume>22</volume><fpage>975</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.07.007</pub-id><?supplied-pmid 27424943?><pub-id pub-id-type="pmid">27424943</pub-id></element-citation></ref><ref id="B16-pathogens-08-00168"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagadesh</surname><given-names>A.</given-names></name><name><surname>Salam</surname><given-names>A.A.</given-names></name><name><surname>Mudgal</surname><given-names>P.P.</given-names></name><name><surname>Arunkumar</surname><given-names>G.</given-names></name></person-group><article-title>Influenza virus neuraminidase (NA): A target for antivirals and vaccines</article-title><source>Arch. Virol.</source><year>2016</year><volume>161</volume><fpage>2087</fpage><lpage>2094</lpage><pub-id pub-id-type="doi">10.1007/s00705-016-2907-7</pub-id><pub-id pub-id-type="pmid">27255748</pub-id></element-citation></ref><ref id="B17-pathogens-08-00168"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B.J.</given-names></name><name><surname>Leser</surname><given-names>G.P.</given-names></name><name><surname>Jackson</surname><given-names>D.</given-names></name><name><surname>Lamb</surname><given-names>R.A.</given-names></name></person-group><article-title>The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>10059</fpage><lpage>10070</lpage><pub-id pub-id-type="doi">10.1128/JVI.01184-08</pub-id><?supplied-pmid 18701586?><pub-id pub-id-type="pmid">18701586</pub-id></element-citation></ref><ref id="B18-pathogens-08-00168"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossman</surname><given-names>J.S.</given-names></name><name><surname>Lamb</surname><given-names>R.A.</given-names></name></person-group><article-title>Influenza virus assembly and budding</article-title><source>Virology</source><year>2011</year><volume>411</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.12.003</pub-id><pub-id pub-id-type="pmid">21237476</pub-id></element-citation></ref><ref id="B19-pathogens-08-00168"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B.J.</given-names></name><name><surname>Leser</surname><given-names>G.P.</given-names></name><name><surname>Morita</surname><given-names>E.</given-names></name><name><surname>Lamb</surname><given-names>R.A.</given-names></name></person-group><article-title>Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>7111</fpage><lpage>7123</lpage><pub-id pub-id-type="doi">10.1128/JVI.00361-07</pub-id><pub-id pub-id-type="pmid">17475660</pub-id></element-citation></ref><ref id="B20-pathogens-08-00168"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayak</surname><given-names>D.P.</given-names></name><name><surname>Hui</surname><given-names>E.K.</given-names></name><name><surname>Barman</surname><given-names>S.</given-names></name></person-group><article-title>Assembly and budding of influenza virus</article-title><source>Virus Res.</source><year>2004</year><volume>106</volume><fpage>147</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2004.08.012</pub-id><pub-id pub-id-type="pmid">15567494</pub-id></element-citation></ref><ref id="B21-pathogens-08-00168"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>A.C.</given-names></name><name><surname>Castelli</surname><given-names>L.A.</given-names></name><name><surname>Lucantoni</surname><given-names>A.C.</given-names></name><name><surname>White</surname><given-names>J.F.</given-names></name><name><surname>Azad</surname><given-names>A.A.</given-names></name><name><surname>Macreadie</surname><given-names>I.G.</given-names></name></person-group><article-title>Expression and analysis of the NS2 protein of influenza A virus</article-title><source>Arch. Virol.</source><year>1995</year><volume>140</volume><fpage>2067</fpage><lpage>2073</lpage><pub-id pub-id-type="doi">10.1007/BF01322693</pub-id><?supplied-pmid 7503702?><pub-id pub-id-type="pmid">7503702</pub-id></element-citation></ref><ref id="B22-pathogens-08-00168"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>J.</given-names></name><name><surname>Nakada</surname><given-names>S.</given-names></name><name><surname>Kato</surname><given-names>A.</given-names></name><name><surname>Toyoda</surname><given-names>T.</given-names></name><name><surname>Ishihama</surname><given-names>A.</given-names></name></person-group><article-title>Molecular assembly of influenza virus: Association of the NS2 protein with virion matrix</article-title><source>Virology</source><year>1993</year><volume>196</volume><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1006/viro.1993.1473</pub-id><?supplied-pmid 8356796?><pub-id pub-id-type="pmid">8356796</pub-id></element-citation></ref><ref id="B23-pathogens-08-00168"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>J.C.</given-names></name><name><surname>Akkina</surname><given-names>R.K.</given-names></name></person-group><article-title>NS2 protein of influenza virus is found in purified virus and phosphorylated in infected cells</article-title><source>Arch. Virol.</source><year>1991</year><volume>116</volume><fpage>69</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/BF01319232</pub-id><?supplied-pmid 1825776?><pub-id pub-id-type="pmid">1825776</pub-id></element-citation></ref><ref id="B24-pathogens-08-00168"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paterson</surname><given-names>D.</given-names></name><name><surname>Fodor</surname><given-names>E.</given-names></name></person-group><article-title>Emerging roles for the influenza A virus nuclear export protein (NEP)</article-title><source>PLoS Pathog.</source><year>2012</year><volume>8</volume><elocation-id>e1003019</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003019</pub-id><?supplied-pmid 23236273?><pub-id pub-id-type="pmid">23236273</pub-id></element-citation></ref><ref id="B25-pathogens-08-00168"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Topham</surname><given-names>D.J.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name></person-group><article-title>Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>708</elocation-id><pub-id pub-id-type="doi">10.3390/v10120708</pub-id></element-citation></ref><ref id="B26-pathogens-08-00168"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Rodriguez</surname><given-names>L.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Topham</surname><given-names>D.J.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group><article-title>Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e00720-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.00720-17</pub-id><?supplied-pmid 28637750?><pub-id pub-id-type="pmid">28637750</pub-id></element-citation></ref><ref id="B27-pathogens-08-00168"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Xiong</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Kong</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Twenty amino acids at the C-terminus of PA-X are associated with increased influenza A virus replication and pathogenicity</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>2036</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1099/vir.0.000143</pub-id><pub-id pub-id-type="pmid">25877935</pub-id></element-citation></ref><ref id="B28-pathogens-08-00168"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Mo</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Gu</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>PA-X-associated early alleviation of the acute lung injury contributes to the attenuation of a highly pathogenic H5N1 avian influenza virus in mice</article-title><source>Med. Microbiol. Immunol.</source><year>2016</year><volume>205</volume><fpage>381</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1007/s00430-016-0461-2</pub-id><?supplied-pmid 27289459?><pub-id pub-id-type="pmid">27289459</pub-id></element-citation></ref><ref id="B29-pathogens-08-00168"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Mo</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Gu</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Hao</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>PA-X decreases the pathogenicity of highly pathogenic H5N1 influenza A virus in avian species by inhibiting virus replication and host response</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>4126</fpage><lpage>4142</lpage><pub-id pub-id-type="doi">10.1128/JVI.02132-14</pub-id><pub-id pub-id-type="pmid">25631083</pub-id></element-citation></ref><ref id="B30-pathogens-08-00168"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaperskyy</surname><given-names>D.A.</given-names></name><name><surname>Schmaling</surname><given-names>S.</given-names></name><name><surname>Larkins-Ford</surname><given-names>J.</given-names></name><name><surname>McCormick</surname><given-names>C.</given-names></name><name><surname>Gaglia</surname><given-names>M.M.</given-names></name></person-group><article-title>Selective Degradation of Host RNA Polymerase II Transcripts by Influenza A Virus PA-X Host Shutoff Protein</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005427</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005427</pub-id><pub-id pub-id-type="pmid">26849127</pub-id></element-citation></ref><ref id="B31-pathogens-08-00168"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>I.G.</given-names></name><name><surname>McCauley</surname><given-names>J.</given-names></name><name><surname>Cox</surname><given-names>N.</given-names></name><name><surname>Daniels</surname><given-names>R.</given-names></name><name><surname>Engelhardt</surname><given-names>O.G.</given-names></name><name><surname>Fukuda</surname><given-names>K.</given-names></name><name><surname>Grohmann</surname><given-names>G.</given-names></name><name><surname>Hay</surname><given-names>A.</given-names></name><name><surname>Kelso</surname><given-names>A.</given-names></name><name><surname>Klimov</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>1156</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.11.043</pub-id><?supplied-pmid 20004635?><pub-id pub-id-type="pmid">20004635</pub-id></element-citation></ref><ref id="B32-pathogens-08-00168"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grohskopf</surname><given-names>L.A.</given-names></name><name><surname>Sokolow</surname><given-names>L.Z.</given-names></name><name><surname>Broder</surname><given-names>K.R.</given-names></name><name><surname>Olsen</surname><given-names>S.J.</given-names></name><name><surname>Karron</surname><given-names>R.A.</given-names></name><name><surname>Jernigan</surname><given-names>D.B.</given-names></name><name><surname>Bresee</surname><given-names>J.S.</given-names></name></person-group><article-title>Prevention and Control of Seasonal Influenza with Vaccines</article-title><source>MMWR Recomm. Rep.</source><year>2016</year><volume>65</volume><fpage>1</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr6505a1</pub-id><?supplied-pmid 27560619?><pub-id pub-id-type="pmid">27560619</pub-id></element-citation></ref><ref id="B33-pathogens-08-00168"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molinari</surname><given-names>N.A.</given-names></name><name><surname>Ortega-Sanchez</surname><given-names>I.R.</given-names></name><name><surname>Messonnier</surname><given-names>M.L.</given-names></name><name><surname>Thompson</surname><given-names>W.W.</given-names></name><name><surname>Wortley</surname><given-names>P.M.</given-names></name><name><surname>Weintraub</surname><given-names>E.</given-names></name><name><surname>Bridges</surname><given-names>C.B.</given-names></name></person-group><article-title>The annual impact of seasonal influenza in the US: Measuring disease burden and costs</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>5086</fpage><lpage>5096</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.03.046</pub-id><?supplied-pmid 17544181?><pub-id pub-id-type="pmid">17544181</pub-id></element-citation></ref><ref id="B34-pathogens-08-00168"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>E.S.</given-names></name><name><surname>Choi</surname><given-names>J.Y.</given-names></name><name><surname>Fieldhouse</surname><given-names>J.K.</given-names></name><name><surname>Borkenhagen</surname><given-names>L.K.</given-names></name><name><surname>Zemke</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Gray</surname><given-names>G.C.</given-names></name></person-group><article-title>The continual threat of influenza virus infections at the human-animal interface: What is new from a one health perspective?</article-title><source>Evol. Med. Public Health</source><year>2018</year><volume>2018</volume><fpage>192</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1093/emph/eoy013</pub-id><?supplied-pmid 30210800?><pub-id pub-id-type="pmid">30210800</pub-id></element-citation></ref><ref id="B35-pathogens-08-00168"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrish</surname><given-names>C.R.</given-names></name><name><surname>Murcia</surname><given-names>P.R.</given-names></name><name><surname>Holmes</surname><given-names>E.C.</given-names></name></person-group><article-title>Influenza virus reservoirs and intermediate hosts: Dogs, horses, and new possibilities for influenza virus exposure of humans</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>2990</fpage><lpage>2994</lpage><pub-id pub-id-type="doi">10.1128/JVI.03146-14</pub-id><?supplied-pmid 25540375?><pub-id pub-id-type="pmid">25540375</pub-id></element-citation></ref><ref id="B36-pathogens-08-00168"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Bourgeois</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Recuenco</surname><given-names>S.</given-names></name><name><surname>Gomez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>New world bats harbor diverse influenza A viruses</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003657</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003657</pub-id><?supplied-pmid 24130481?><pub-id pub-id-type="pmid">24130481</pub-id></element-citation></ref><ref id="B37-pathogens-08-00168"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>S.W.</given-names></name><name><surname>Webby</surname><given-names>R.J.</given-names></name><name><surname>Webster</surname><given-names>R.G.</given-names></name></person-group><article-title>Evolution and ecology of influenza A viruses</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2014</year><volume>385</volume><fpage>359</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1007/82_2014_396</pub-id><?supplied-pmid 24990620?><pub-id pub-id-type="pmid">24990620</pub-id></element-citation></ref><ref id="B38-pathogens-08-00168"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>A.M.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Anderson</surname><given-names>C.S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Zand</surname><given-names>M.S.</given-names></name><name><surname>Sangster</surname><given-names>M.Y.</given-names></name><name><surname>Topham</surname><given-names>D.J.</given-names></name></person-group><article-title>Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0188267</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0188267</pub-id><pub-id pub-id-type="pmid">29145498</pub-id></element-citation></ref><ref id="B39-pathogens-08-00168"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grohskopf</surname><given-names>L.A.</given-names></name><name><surname>Sokolow</surname><given-names>L.Z.</given-names></name><name><surname>Broder</surname><given-names>K.R.</given-names></name><name><surname>Walter</surname><given-names>E.B.</given-names></name><name><surname>Bresee</surname><given-names>J.S.</given-names></name><name><surname>Fry</surname><given-names>A.M.</given-names></name><name><surname>Jernigan</surname><given-names>D.B.</given-names></name></person-group><article-title>Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices&#x02014;United States, 2017&#x02013;2018 Influenza Season</article-title><source>MMWR Recomm. Rep.</source><year>2017</year><volume>66</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr6602a1</pub-id><?supplied-pmid 28841201?><pub-id pub-id-type="pmid">28841201</pub-id></element-citation></ref><ref id="B40-pathogens-08-00168"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garten</surname><given-names>R.J.</given-names></name><name><surname>Davis</surname><given-names>C.T.</given-names></name><name><surname>Russell</surname><given-names>C.A.</given-names></name><name><surname>Shu</surname><given-names>B.</given-names></name><name><surname>Lindstrom</surname><given-names>S.</given-names></name><name><surname>Balish</surname><given-names>A.</given-names></name><name><surname>Sessions</surname><given-names>W.M.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Skepner</surname><given-names>E.</given-names></name><name><surname>Deyde</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans</article-title><source>Science</source><year>2009</year><volume>325</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1126/science.1176225</pub-id><pub-id pub-id-type="pmid">19465683</pub-id></element-citation></ref><ref id="B41-pathogens-08-00168"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>G.J.</given-names></name><name><surname>Vijaykrishna</surname><given-names>D.</given-names></name><name><surname>Bahl</surname><given-names>J.</given-names></name><name><surname>Lycett</surname><given-names>S.J.</given-names></name><name><surname>Worobey</surname><given-names>M.</given-names></name><name><surname>Pybus</surname><given-names>O.G.</given-names></name><name><surname>Ma</surname><given-names>S.K.</given-names></name><name><surname>Cheung</surname><given-names>C.L.</given-names></name><name><surname>Raghwani</surname><given-names>J.</given-names></name><name><surname>Bhatt</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic</article-title><source>Nature</source><year>2009</year><volume>459</volume><fpage>1122</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1038/nature08182</pub-id><?supplied-pmid 19516283?><pub-id pub-id-type="pmid">19516283</pub-id></element-citation></ref><ref id="B42-pathogens-08-00168"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>S.F.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Santiago</surname><given-names>F.W.</given-names></name><name><surname>Topham</surname><given-names>D.J.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group><article-title>Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA)</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>3562</fpage><lpage>3570</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.049</pub-id><?supplied-pmid 26044496?><pub-id pub-id-type="pmid">26044496</pub-id></element-citation></ref><ref id="B43-pathogens-08-00168"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group><article-title>Reverse Genetics Approaches for the Development of Influenza Vaccines</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>18</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18010020</pub-id><?supplied-pmid 28025504?><pub-id pub-id-type="pmid">28025504</pub-id></element-citation></ref><ref id="B44-pathogens-08-00168"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schotsaert</surname><given-names>M.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Inactivated influenza virus vaccines: The future of TIV and QIV</article-title><source>Curr. Opin. Virol.</source><year>2017</year><volume>23</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.04.005</pub-id><?supplied-pmid 28505524?><pub-id pub-id-type="pmid">28505524</pub-id></element-citation></ref><ref id="B45-pathogens-08-00168"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>R.J.</given-names></name><name><surname>Cooper</surname><given-names>K.L.</given-names></name><name><surname>Tappenden</surname><given-names>P.</given-names></name><name><surname>Rees</surname><given-names>A.</given-names></name><name><surname>Simpson</surname><given-names>E.L.</given-names></name><name><surname>Read</surname><given-names>R.C.</given-names></name><name><surname>Nicholson</surname><given-names>K.G.</given-names></name></person-group><article-title>Oseltamivir, zanamivir and amantadine in the prevention of influenza: A systematic review</article-title><source>J. Infect.</source><year>2011</year><volume>62</volume><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2010.10.003</pub-id><?supplied-pmid 20950645?><pub-id pub-id-type="pmid">20950645</pub-id></element-citation></ref><ref id="B46-pathogens-08-00168"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Lobo</surname><given-names>P.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Rodriguez</surname><given-names>L.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group><article-title>Novel Approaches for The Development of Live Attenuated Influenza Vaccines</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>190</elocation-id><pub-id pub-id-type="doi">10.3390/v11020190</pub-id><?supplied-pmid 30813325?><pub-id pub-id-type="pmid">30813325</pub-id></element-citation></ref><ref id="B47-pathogens-08-00168"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>T.Y.</given-names></name><name><surname>Brass</surname><given-names>A.L.</given-names></name></person-group><article-title>Host genetic determinants of influenza pathogenicity</article-title><source>Curr. Opin. Virol.</source><year>2013</year><volume>3</volume><fpage>531</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2013.07.005</pub-id><?supplied-pmid 23933004?><pub-id pub-id-type="pmid">23933004</pub-id></element-citation></ref><ref id="B48-pathogens-08-00168"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>C.M.</given-names></name><name><surname>Chughtai</surname><given-names>A.A.</given-names></name><name><surname>Adam</surname><given-names>D.C.</given-names></name><name><surname>MacIntyre</surname><given-names>C.R.</given-names></name></person-group><article-title>An overview of the epidemiology and emergence of influenza A infection in humans over time</article-title><source>Arch. Public Health</source><year>2017</year><volume>75</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13690-017-0182-z</pub-id><?supplied-pmid 28352464?><pub-id pub-id-type="pmid">28352464</pub-id></element-citation></ref><ref id="B49-pathogens-08-00168"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>D.R.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>H5N1, a wealth of knowledge to improve pandemic preparedness</article-title><source>Virus Res.</source><year>2013</year><volume>178</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2013.11.001</pub-id><?supplied-pmid 24238658?><pub-id pub-id-type="pmid">24238658</pub-id></element-citation></ref><ref id="B50-pathogens-08-00168"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A.</given-names></name><name><surname>Pillai</surname><given-names>P.S.</given-names></name></person-group><article-title>Innate immunity to influenza virus infection</article-title><source>Nat. Rev. Immunol.</source><year>2014</year><volume>14</volume><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/nri3665</pub-id><?supplied-pmid 24762827?><pub-id pub-id-type="pmid">24762827</pub-id></element-citation></ref><ref id="B51-pathogens-08-00168"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>P.H.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Yao</surname><given-names>S.</given-names></name><name><surname>Cottam</surname><given-names>H.B.</given-names></name><name><surname>Tan</surname><given-names>G.S.</given-names></name><name><surname>Crain</surname><given-names>B.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Messer</surname><given-names>K.</given-names></name><name><surname>Pu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><pub-id pub-id-type="doi">10.1128/JVI.01050-17</pub-id><?supplied-pmid 28724768?><pub-id pub-id-type="pmid">28724768</pub-id></element-citation></ref><ref id="B52-pathogens-08-00168"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber-Gerlach</surname><given-names>M.</given-names></name><name><surname>Weber</surname><given-names>F.</given-names></name></person-group><article-title>Standing on three legs: Antiviral activities of RIG-I against influenza viruses</article-title><source>Curr. Opin. Immunol.</source><year>2016</year><volume>42</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2016.05.016</pub-id><?supplied-pmid 27318973?><pub-id pub-id-type="pmid">27318973</pub-id></element-citation></ref><ref id="B53-pathogens-08-00168"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarvestani</surname><given-names>S.T.</given-names></name><name><surname>McAuley</surname><given-names>J.L.</given-names></name></person-group><article-title>The role of the NLRP3 inflammasome in regulation of antiviral responses to influenza A virus infection</article-title><source>Antivir. Res.</source><year>2017</year><volume>148</volume><fpage>32</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.10.020</pub-id><?supplied-pmid 29097227?><pub-id pub-id-type="pmid">29097227</pub-id></element-citation></ref><ref id="B54-pathogens-08-00168"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Alcorn</surname><given-names>J.F.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Pilewski</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Kolls</surname><given-names>J.K.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>AIM2 Inflammasome Is Critical for Influenza-Induced Lung Injury and Mortality</article-title><source>J. Immunol.</source><year>2017</year><volume>198</volume><fpage>4383</fpage><lpage>4393</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600714</pub-id><?supplied-pmid 28424239?><pub-id pub-id-type="pmid">28424239</pub-id></element-citation></ref><ref id="B55-pathogens-08-00168"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>T.</given-names></name><name><surname>Ludwig</surname><given-names>S.</given-names></name></person-group><article-title>Influenza viruses control the vertebrate type I interferon system: Factors, mechanisms, and consequences</article-title><source>J. Interferon Cytokine Res.</source><year>2009</year><volume>29</volume><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1089/jir.2009.0066</pub-id><?supplied-pmid 19708812?><pub-id pub-id-type="pmid">19708812</pub-id></element-citation></ref><ref id="B56-pathogens-08-00168"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermant</surname><given-names>P.</given-names></name><name><surname>Michiels</surname><given-names>T.</given-names></name></person-group><article-title>Interferon-lambda in the context of viral infections: Production, response and therapeutic implications</article-title><source>J. Innate Immun.</source><year>2014</year><volume>6</volume><fpage>563</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1159/000360084</pub-id><?supplied-pmid 24751921?><pub-id pub-id-type="pmid">24751921</pub-id></element-citation></ref><ref id="B57-pathogens-08-00168"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>T.H.</given-names></name><name><surname>Paludan</surname><given-names>S.R.</given-names></name></person-group><article-title>Molecular pathways in virus-induced cytokine production</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2001</year><volume>65</volume><fpage>131</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1128/MMBR.65.1.131-150.2001</pub-id><pub-id pub-id-type="pmid">11238989</pub-id></element-citation></ref><ref id="B58-pathogens-08-00168"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotta</surname><given-names>S.</given-names></name><name><surname>Davidson</surname><given-names>S.</given-names></name><name><surname>Mahlakoiv</surname><given-names>T.</given-names></name><name><surname>Desmet</surname><given-names>C.J.</given-names></name><name><surname>Buckwalter</surname><given-names>M.R.</given-names></name><name><surname>Albert</surname><given-names>M.L.</given-names></name><name><surname>Staeheli</surname><given-names>P.</given-names></name><name><surname>Wack</surname><given-names>A.</given-names></name></person-group><article-title>Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003773</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003773</pub-id><?supplied-pmid 24278020?><pub-id pub-id-type="pmid">24278020</pub-id></element-citation></ref><ref id="B59-pathogens-08-00168"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>T.M.</given-names></name><name><surname>Marin</surname><given-names>M.</given-names></name><name><surname>Chin</surname><given-names>C.R.</given-names></name><name><surname>Savidis</surname><given-names>G.</given-names></name><name><surname>Brass</surname><given-names>A.L.</given-names></name><name><surname>Melikyan</surname><given-names>G.B.</given-names></name></person-group><article-title>IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><elocation-id>e1004048</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004048</pub-id><pub-id pub-id-type="pmid">24699674</pub-id></element-citation></ref><ref id="B60-pathogens-08-00168"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D.E.</given-names></name><name><surname>Marie</surname><given-names>I.J.</given-names></name><name><surname>Durbin</surname><given-names>J.E.</given-names></name></person-group><article-title>Induction and function of type I and III interferon in response to viral infection</article-title><source>Curr. Opin. Virol.</source><year>2011</year><volume>1</volume><fpage>476</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2011.11.001</pub-id><pub-id pub-id-type="pmid">22323926</pub-id></element-citation></ref><ref id="B61-pathogens-08-00168"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>C.</given-names></name><name><surname>Levy</surname><given-names>D.E.</given-names></name><name><surname>Decker</surname><given-names>T.</given-names></name></person-group><article-title>JAK-STAT signaling: From interferons to cytokines</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>20059</fpage><lpage>20063</lpage><pub-id pub-id-type="doi">10.1074/jbc.R700016200</pub-id><?supplied-pmid 17502367?><pub-id pub-id-type="pmid">17502367</pub-id></element-citation></ref><ref id="B62-pathogens-08-00168"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenoever</surname><given-names>B.R.</given-names></name><name><surname>Ng</surname><given-names>S.L.</given-names></name><name><surname>Chua</surname><given-names>M.A.</given-names></name><name><surname>McWhirter</surname><given-names>S.M.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Maniatis</surname><given-names>T.</given-names></name></person-group><article-title>Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity</article-title><source>Science</source><year>2007</year><volume>315</volume><fpage>1274</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1126/science.1136567</pub-id><?supplied-pmid 17332413?><pub-id pub-id-type="pmid">17332413</pub-id></element-citation></ref><ref id="B63-pathogens-08-00168"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>S.L.</given-names></name><name><surname>Friedman</surname><given-names>B.A.</given-names></name><name><surname>Schmid</surname><given-names>S.</given-names></name><name><surname>Gertz</surname><given-names>J.</given-names></name><name><surname>Myers</surname><given-names>R.M.</given-names></name><name><surname>tenOever</surname><given-names>B.R.</given-names></name><name><surname>Maniatis</surname><given-names>T.</given-names></name></person-group><article-title>I kappa B kinase epsilon (IKK epsilon) regulates the balance between type I and type II interferon responses</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>21170</fpage><lpage>21175</lpage><pub-id pub-id-type="doi">10.1073/pnas.1119137109</pub-id><?supplied-pmid 22171011?><pub-id pub-id-type="pmid">22171011</pub-id></element-citation></ref><ref id="B64-pathogens-08-00168"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>H.H.</given-names></name><name><surname>Schneider</surname><given-names>W.M.</given-names></name><name><surname>Rice</surname><given-names>C.M.</given-names></name></person-group><article-title>Interferons and viruses: An evolutionary arms race of molecular interactions</article-title><source>Trends Immunol.</source><year>2015</year><volume>36</volume><fpage>124</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.it.2015.01.004</pub-id><?supplied-pmid 25704559?><pub-id pub-id-type="pmid">25704559</pub-id></element-citation></ref><ref id="B65-pathogens-08-00168"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>F.J.</given-names></name><name><surname>Engleman</surname><given-names>E.G.</given-names></name></person-group><article-title>Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells</article-title><source>Cell. Immunol.</source><year>1996</year><volume>173</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1006/cimm.1996.0245</pub-id><?supplied-pmid 8871595?><pub-id pub-id-type="pmid">8871595</pub-id></element-citation></ref><ref id="B66-pathogens-08-00168"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.S.</given-names></name><name><surname>Draghi</surname><given-names>M.</given-names></name><name><surname>Mahmood</surname><given-names>K.</given-names></name><name><surname>Holmes</surname><given-names>T.H.</given-names></name><name><surname>Kemble</surname><given-names>G.W.</given-names></name><name><surname>Dekker</surname><given-names>C.L.</given-names></name><name><surname>Arvin</surname><given-names>A.M.</given-names></name><name><surname>Parham</surname><given-names>P.</given-names></name><name><surname>Greenberg</surname><given-names>H.B.</given-names></name></person-group><article-title>T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus</article-title><source>J. Clin. Investig.</source><year>2004</year><volume>114</volume><fpage>1812</fpage><lpage>1819</lpage><pub-id pub-id-type="doi">10.1172/JCI22797</pub-id><pub-id pub-id-type="pmid">15599406</pub-id></element-citation></ref><ref id="B67-pathogens-08-00168"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>Y.</given-names></name><name><surname>Moki</surname><given-names>T.</given-names></name><name><surname>Takizawa</surname><given-names>T.</given-names></name><name><surname>Shiratsuchi</surname><given-names>A.</given-names></name><name><surname>Nakanishi</surname><given-names>Y.</given-names></name></person-group><article-title>Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice</article-title><source>J. Immunol.</source><year>2007</year><volume>178</volume><fpage>2448</fpage><lpage>2457</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.4.2448</pub-id><pub-id pub-id-type="pmid">17277152</pub-id></element-citation></ref><ref id="B68-pathogens-08-00168"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legge</surname><given-names>K.L.</given-names></name><name><surname>Braciale</surname><given-names>T.J.</given-names></name></person-group><article-title>Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection</article-title><source>Immunity</source><year>2003</year><volume>18</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(03)00023-2</pub-id><pub-id pub-id-type="pmid">12594953</pub-id></element-citation></ref><ref id="B69-pathogens-08-00168"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legge</surname><given-names>K.L.</given-names></name><name><surname>Braciale</surname><given-names>T.J.</given-names></name></person-group><article-title>Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression</article-title><source>Immunity</source><year>2005</year><volume>23</volume><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.11.006</pub-id><pub-id pub-id-type="pmid">16356862</pub-id></element-citation></ref><ref id="B70-pathogens-08-00168"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>C.</given-names></name><name><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group><article-title>Antiviral B cell and T cell immunity in the lungs</article-title><source>Nat. Immunol.</source><year>2015</year><volume>16</volume><fpage>18</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/ni.3056</pub-id><pub-id pub-id-type="pmid">25521681</pub-id></element-citation></ref><ref id="B71-pathogens-08-00168"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarda</surname><given-names>G.</given-names></name><name><surname>Zenger</surname><given-names>M.</given-names></name><name><surname>Yazdi</surname><given-names>A.S.</given-names></name><name><surname>Schroder</surname><given-names>K.</given-names></name><name><surname>Ferrero</surname><given-names>I.</given-names></name><name><surname>Menu</surname><given-names>P.</given-names></name><name><surname>Tardivel</surname><given-names>A.</given-names></name><name><surname>Mattmann</surname><given-names>C.</given-names></name><name><surname>Tschopp</surname><given-names>J.</given-names></name></person-group><article-title>Differential expression of NLRP3 among hematopoietic cells</article-title><source>J. Immunol.</source><year>2011</year><volume>186</volume><fpage>2529</fpage><lpage>2534</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002720</pub-id><?supplied-pmid 21257968?><pub-id pub-id-type="pmid">21257968</pub-id></element-citation></ref><ref id="B72-pathogens-08-00168"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pothlichet</surname><given-names>J.</given-names></name><name><surname>Meunier</surname><given-names>I.</given-names></name><name><surname>Davis</surname><given-names>B.K.</given-names></name><name><surname>Ting</surname><given-names>J.P.</given-names></name><name><surname>Skamene</surname><given-names>E.</given-names></name><name><surname>von Messling</surname><given-names>V.</given-names></name><name><surname>Vidal</surname><given-names>S.M.</given-names></name></person-group><article-title>Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003256</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003256</pub-id><?supplied-pmid 23592984?><pub-id pub-id-type="pmid">23592984</pub-id></element-citation></ref><ref id="B73-pathogens-08-00168"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupfer</surname><given-names>C.</given-names></name><name><surname>Kanneganti</surname><given-names>T.D.</given-names></name></person-group><article-title>The expanding role of NLRs in antiviral immunity</article-title><source>Immunol. Rev.</source><year>2013</year><volume>255</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/imr.12089</pub-id><?supplied-pmid 23947344?><pub-id pub-id-type="pmid">23947344</pub-id></element-citation></ref><ref id="B74-pathogens-08-00168"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>I.C.</given-names></name><name><surname>Scull</surname><given-names>M.A.</given-names></name><name><surname>Moore</surname><given-names>C.B.</given-names></name><name><surname>Holl</surname><given-names>E.K.</given-names></name><name><surname>McElvania-TeKippe</surname><given-names>E.</given-names></name><name><surname>Taxman</surname><given-names>D.J.</given-names></name><name><surname>Guthrie</surname><given-names>E.H.</given-names></name><name><surname>Pickles</surname><given-names>R.J.</given-names></name><name><surname>Ting</surname><given-names>J.P.</given-names></name></person-group><article-title>The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA</article-title><source>Immunity</source><year>2009</year><volume>30</volume><fpage>556</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.02.005</pub-id><?supplied-pmid 19362020?><pub-id pub-id-type="pmid">19362020</pub-id></element-citation></ref><ref id="B75-pathogens-08-00168"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAuley</surname><given-names>J.L.</given-names></name><name><surname>Tate</surname><given-names>M.D.</given-names></name><name><surname>MacKenzie-Kludas</surname><given-names>C.J.</given-names></name><name><surname>Pinar</surname><given-names>A.</given-names></name><name><surname>Zeng</surname><given-names>W.</given-names></name><name><surname>Stutz</surname><given-names>A.</given-names></name><name><surname>Latz</surname><given-names>E.</given-names></name><name><surname>Brown</surname><given-names>L.E.</given-names></name><name><surname>Mansell</surname><given-names>A.</given-names></name></person-group><article-title>Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003392</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003392</pub-id><?supplied-pmid 23737748?><pub-id pub-id-type="pmid">23737748</pub-id></element-citation></ref><ref id="B76-pathogens-08-00168"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichinohe</surname><given-names>T.</given-names></name><name><surname>Pang</surname><given-names>I.K.</given-names></name><name><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>Influenza virus activates inflammasomes via its intracellular M2 ion channel</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/ni.1861</pub-id><?supplied-pmid 20383149?><pub-id pub-id-type="pmid">20383149</pub-id></element-citation></ref><ref id="B77-pathogens-08-00168"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>P.</given-names></name><name><surname>Nawadkar</surname><given-names>R.</given-names></name><name><surname>Ojha</surname><given-names>H.</given-names></name><name><surname>Kumar</surname><given-names>J.</given-names></name><name><surname>Sahu</surname><given-names>A.</given-names></name></person-group><article-title>Complement Evasion Strategies of Viruses: An Overview</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>1117</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.01117</pub-id><pub-id pub-id-type="pmid">28670306</pub-id></element-citation></ref><ref id="B78-pathogens-08-00168"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishore</surname><given-names>U.</given-names></name><name><surname>Reid</surname><given-names>K.B.</given-names></name></person-group><article-title>C1q: Structure, function, and receptors</article-title><source>Immunopharmacology</source><year>2000</year><volume>49</volume><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/S0162-3109(00)80301-X</pub-id><pub-id pub-id-type="pmid">10904115</pub-id></element-citation></ref><ref id="B79-pathogens-08-00168"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.D.</given-names></name><name><surname>Song</surname><given-names>W.C.</given-names></name></person-group><article-title>Membrane complement regulatory proteins</article-title><source>Clin. Immunol.</source><year>2006</year><volume>118</volume><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2005.10.014</pub-id><pub-id pub-id-type="pmid">16338172</pub-id></element-citation></ref><ref id="B80-pathogens-08-00168"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name></person-group><article-title>The role of C5a in acute lung injury induced by highly pathogenic viral infections</article-title><source>Emerg Microbes Infect</source><year>2015</year><volume>4</volume><fpage>e28</fpage><pub-id pub-id-type="doi">10.1038/emi.2015.28</pub-id><pub-id pub-id-type="pmid">26060601</pub-id></element-citation></ref><ref id="B81-pathogens-08-00168"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>P.Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Detection of single nucleotide polymorphisms</article-title><source>Curr. Issues Mol. Biol.</source><year>2003</year><volume>5</volume><fpage>43</fpage><lpage>60</lpage><?supplied-pmid 12793528?><pub-id pub-id-type="pmid">12793528</pub-id></element-citation></ref><ref id="B82-pathogens-08-00168"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Bello</surname><given-names>J.</given-names></name><name><surname>Jimenez-Morales</surname><given-names>M.</given-names></name></person-group><article-title>Functional implications of single nucleotide polymorphisms (SNPs) in protein-coding and non-coding RNA genes in multifactorial diseases</article-title><source>Gac. Med. Mex.</source><year>2017</year><volume>153</volume><fpage>238</fpage><lpage>250</lpage><?supplied-pmid 28474710?><pub-id pub-id-type="pmid">28474710</pub-id></element-citation></ref><ref id="B83-pathogens-08-00168"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Bello</surname><given-names>J.</given-names></name><name><surname>Vargas-Alarcon</surname><given-names>G.</given-names></name><name><surname>Tovilla-Zarate</surname><given-names>C.</given-names></name><name><surname>Fragoso</surname><given-names>J.M.</given-names></name></person-group><article-title>Single nucleotide polymorphisms (SNPs): Functional implications of regulatory-SNP (rSNP) and structural RNA (srSNPs) in complex diseases</article-title><source>Gac. Med. Mex.</source><year>2013</year><volume>149</volume><fpage>220</fpage><lpage>228</lpage><?supplied-pmid 23652189?><pub-id pub-id-type="pmid">23652189</pub-id></element-citation></ref><ref id="B84-pathogens-08-00168"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skevaki</surname><given-names>C.</given-names></name><name><surname>Pararas</surname><given-names>M.</given-names></name><name><surname>Kostelidou</surname><given-names>K.</given-names></name><name><surname>Tsakris</surname><given-names>A.</given-names></name><name><surname>Routsias</surname><given-names>J.G.</given-names></name></person-group><article-title>Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases</article-title><source>Clin. Exp. Immunol.</source><year>2015</year><volume>180</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1111/cei.12578</pub-id><?supplied-pmid 25560985?><pub-id pub-id-type="pmid">25560985</pub-id></element-citation></ref><ref id="B85-pathogens-08-00168"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>A.V.</given-names></name></person-group><article-title>The genomics and genetics of human infectious disease susceptibility</article-title><source>Annu. Rev. Genom. Hum. Genet.</source><year>2001</year><volume>2</volume><fpage>373</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1146/annurev.genom.2.1.373</pub-id></element-citation></ref><ref id="B86-pathogens-08-00168"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>W.</given-names></name><name><surname>Ye</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Su</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Meta-analysis of the relationship between single nucleotide polymorphism of IL-10-1082G/A and rheumatic heart disease</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>12343</fpage><lpage>12350</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23901</pub-id><?supplied-pmid 29552315?><pub-id pub-id-type="pmid">29552315</pub-id></element-citation></ref><ref id="B87-pathogens-08-00168"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koberle</surname><given-names>B.</given-names></name><name><surname>Koch</surname><given-names>B.</given-names></name><name><surname>Fischer</surname><given-names>B.M.</given-names></name><name><surname>Hartwig</surname><given-names>A.</given-names></name></person-group><article-title>Single nucleotide polymorphisms in DNA repair genes and putative cancer risk</article-title><source>Arch Toxicol</source><year>2016</year><volume>90</volume><fpage>2369</fpage><lpage>2388</lpage><pub-id pub-id-type="doi">10.1007/s00204-016-1771-2</pub-id><pub-id pub-id-type="pmid">27334373</pub-id></element-citation></ref><ref id="B88-pathogens-08-00168"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Mei</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name></person-group><article-title>The association between the UBQLN1 polymorphism and Alzheimer&#x02019;s disease risk: A systematic review</article-title><source>Cell. Mol. Biol.</source><year>2017</year><volume>63</volume><fpage>94</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.14715/cmb/2017.63.5.17</pub-id></element-citation></ref><ref id="B89-pathogens-08-00168"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luykx</surname><given-names>J.J.</given-names></name><name><surname>Broersen</surname><given-names>J.L.</given-names></name><name><surname>de Leeuw</surname><given-names>M.</given-names></name></person-group><article-title>The DRD2 rs1076560 polymorphism and schizophrenia-related intermediate phenotypes: A systematic review and meta-analysis</article-title><source>Neurosci. Biobehav. Rev.</source><year>2017</year><volume>74</volume><fpage>214</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.01.006</pub-id><pub-id pub-id-type="pmid">28104410</pub-id></element-citation></ref><ref id="B90-pathogens-08-00168"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>V.</given-names></name><name><surname>Bullock</surname><given-names>K.</given-names></name><name><surname>Greenhalf</surname><given-names>W.</given-names></name></person-group><article-title>Single-Nucleotide Polymorphism to Associate Cancer Risk</article-title><source>Methods Mol. Biol.</source><year>2016</year><volume>1381</volume><fpage>93</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-3204-7_6</pub-id><pub-id pub-id-type="pmid">26667457</pub-id></element-citation></ref><ref id="B91-pathogens-08-00168"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Bai</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name></person-group><article-title>MicroRNA single-nucleotide polymorphisms and diabetes mellitus: A comprehensive review</article-title><source>Clin. Genet.</source><year>2019</year><volume>95</volume><fpage>451</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1111/cge.13491</pub-id><?supplied-pmid 30536647?><pub-id pub-id-type="pmid">30536647</pub-id></element-citation></ref><ref id="B92-pathogens-08-00168"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imahara</surname><given-names>S.D.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>G.E.</given-names></name></person-group><article-title>Genetic determinants of the inflammatory response</article-title><source>Curr. Opin. Crit. Care</source><year>2004</year><volume>10</volume><fpage>318</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1097/01.ccx.0000140942.42247.7e</pub-id><?supplied-pmid 15385745?><pub-id pub-id-type="pmid">15385745</pub-id></element-citation></ref><ref id="B93-pathogens-08-00168"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>T.L.</given-names></name><name><surname>Lima</surname><given-names>R.E.</given-names></name><name><surname>Goes</surname><given-names>G.H.B.</given-names></name><name><surname>Pereira</surname><given-names>L.A.</given-names></name><name><surname>Fernandes</surname><given-names>M.S.S.</given-names></name><name><surname>Moura</surname><given-names>P.</given-names></name><name><surname>Vasconcelos</surname><given-names>L.R.S.</given-names></name><name><surname>Correia</surname><given-names>C.C.</given-names></name></person-group><article-title>Cognitive Dysfunction and Single Nucleotide Polymorphisms in Hepatitis C Virus-Infected Persons: A Systematic Review</article-title><source>Viral Immunol.</source><year>2017</year><volume>30</volume><fpage>703</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1089/vim.2017.0084</pub-id><?supplied-pmid 29016246?><pub-id pub-id-type="pmid">29016246</pub-id></element-citation></ref><ref id="B94-pathogens-08-00168"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaeger</surname><given-names>M.</given-names></name><name><surname>Stappers</surname><given-names>M.H.</given-names></name><name><surname>Joosten</surname><given-names>L.A.</given-names></name><name><surname>Gyssens</surname><given-names>I.C.</given-names></name><name><surname>Netea</surname><given-names>M.G.</given-names></name></person-group><article-title>Genetic variation in pattern recognition receptors: Functional consequences and susceptibility to infectious disease</article-title><source>Future Med.</source><year>2015</year><volume>10</volume><pub-id pub-id-type="doi">10.2217/fmb.15.37</pub-id><?supplied-pmid 26059622?><pub-id pub-id-type="pmid">26059622</pub-id></element-citation></ref><ref id="B95-pathogens-08-00168"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenney</surname><given-names>A.D.</given-names></name><name><surname>Dowdle</surname><given-names>J.A.</given-names></name><name><surname>Bozzacco</surname><given-names>L.</given-names></name><name><surname>McMichael</surname><given-names>T.M.</given-names></name><name><surname>St Gelais</surname><given-names>C.</given-names></name><name><surname>Panfil</surname><given-names>A.R.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Schlesinger</surname><given-names>L.S.</given-names></name><name><surname>Anderson</surname><given-names>M.Z.</given-names></name><name><surname>Green</surname><given-names>P.L.</given-names></name><etal/></person-group><article-title>Human Genetic Determinants of Viral Diseases</article-title><source>Annu. Rev. Genet.</source><year>2017</year><volume>51</volume><fpage>241</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-120116-023425</pub-id><?supplied-pmid 28853921?><pub-id pub-id-type="pmid">28853921</pub-id></element-citation></ref><ref id="B96-pathogens-08-00168"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>S.</given-names></name><name><surname>Abdel-Hafiz</surname><given-names>H.</given-names></name><name><surname>Raza</surname><given-names>A.</given-names></name><name><surname>Fatima</surname><given-names>K.</given-names></name><name><surname>Qadri</surname><given-names>I.</given-names></name></person-group><article-title>Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma</article-title><source>World J. Hepatol.</source><year>2016</year><volume>8</volume><fpage>485</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.4254/wjh.v8.i10.485</pub-id><?supplied-pmid 27057306?><pub-id pub-id-type="pmid">27057306</pub-id></element-citation></ref><ref id="B97-pathogens-08-00168"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>S.U.</given-names></name><name><surname>Rauf</surname><given-names>M.</given-names></name><name><surname>Abbas</surname><given-names>Z.</given-names></name><name><surname>Hamed</surname><given-names>M.H.</given-names></name><name><surname>Qadri</surname><given-names>I.</given-names></name></person-group><article-title>Role of Some Predominant Host Immunomodulators&#x02019; Single Nucleotide Polymorphisms in Severity of Hepatitis B Virus and Hepatitis C Virus Infection</article-title><source>Viral Immunol.</source><year>2016</year><volume>29</volume><fpage>536</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1089/vim.2016.0062</pub-id><?supplied-pmid 27676210?><pub-id pub-id-type="pmid">27676210</pub-id></element-citation></ref><ref id="B98-pathogens-08-00168"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidaka</surname><given-names>F.</given-names></name><name><surname>Matsuo</surname><given-names>S.</given-names></name><name><surname>Muta</surname><given-names>T.</given-names></name><name><surname>Takeshige</surname><given-names>K.</given-names></name><name><surname>Mizukami</surname><given-names>T.</given-names></name><name><surname>Nunoi</surname><given-names>H.</given-names></name></person-group><article-title>A missense mutation of the Toll-like receptor 3 gene in a patient with influenza-associated encephalopathy</article-title><source>Clin. Immunol.</source><year>2006</year><volume>119</volume><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2006.01.005</pub-id><pub-id pub-id-type="pmid">16517210</pub-id></element-citation></ref><ref id="B99-pathogens-08-00168"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>S.</given-names></name><name><surname>Molteni</surname><given-names>C.G.</given-names></name><name><surname>Giliani</surname><given-names>S.</given-names></name><name><surname>Mazza</surname><given-names>C.</given-names></name><name><surname>Scala</surname><given-names>A.</given-names></name><name><surname>Tagliaferri</surname><given-names>L.</given-names></name><name><surname>Pelucchi</surname><given-names>C.</given-names></name><name><surname>Fossali</surname><given-names>E.</given-names></name><name><surname>Plebani</surname><given-names>A.</given-names></name><name><surname>Principi</surname><given-names>N.</given-names></name></person-group><article-title>Toll-like receptor 3 gene polymorphisms and severity of pandemic A/H1N1/2009 influenza in otherwise healthy children</article-title><source>Virol J.</source><year>2012</year><volume>9</volume><fpage>270</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-9-270</pub-id><pub-id pub-id-type="pmid">23151015</pub-id></element-citation></ref><ref id="B100-pathogens-08-00168"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Ke</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Tam</surname><given-names>C.H.T.</given-names></name><name><surname>Ma</surname><given-names>R.C.W.</given-names></name><name><surname>Guan</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><etal/></person-group><article-title>IFITM3, TLR3, and CD55 Gene SNPs and Cumulative Genetic Risks for Severe Outcomes in Chinese Patients With H7N9/H1N1pdm09 Influenza</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>216</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix235</pub-id><pub-id pub-id-type="pmid">28510725</pub-id></element-citation></ref><ref id="B101-pathogens-08-00168"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Her</surname><given-names>Z.</given-names></name><name><surname>Teng</surname><given-names>T.S.</given-names></name><name><surname>Tan</surname><given-names>J.J.</given-names></name><name><surname>Teo</surname><given-names>T.H.</given-names></name><name><surname>Kam</surname><given-names>Y.W.</given-names></name><name><surname>Lum</surname><given-names>F.M.</given-names></name><name><surname>Lee</surname><given-names>W.W.</given-names></name><name><surname>Gabriel</surname><given-names>C.</given-names></name><name><surname>Melchiotti</surname><given-names>R.</given-names></name><name><surname>Andiappan</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response</article-title><source>EMBO Mol. Med.</source><year>2015</year><volume>7</volume><fpage>24</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.15252/emmm.201404459</pub-id><?supplied-pmid 25452586?><pub-id pub-id-type="pmid">25452586</pub-id></element-citation></ref><ref id="B102-pathogens-08-00168"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.Y.</given-names></name><name><surname>Jouanguy</surname><given-names>E.</given-names></name><name><surname>Ugolini</surname><given-names>S.</given-names></name><name><surname>Smahi</surname><given-names>A.</given-names></name><name><surname>Elain</surname><given-names>G.</given-names></name><name><surname>Romero</surname><given-names>P.</given-names></name><name><surname>Segal</surname><given-names>D.</given-names></name><name><surname>Sancho-Shimizu</surname><given-names>V.</given-names></name><name><surname>Lorenzo</surname><given-names>L.</given-names></name><name><surname>Puel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>TLR3 deficiency in patients with herpes simplex encephalitis</article-title><source>Science</source><year>2007</year><volume>317</volume><fpage>1522</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.1126/science.1139522</pub-id><?supplied-pmid 17872438?><pub-id pub-id-type="pmid">17872438</pub-id></element-citation></ref><ref id="B103-pathogens-08-00168"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafaille</surname><given-names>F.G.</given-names></name><name><surname>Pessach</surname><given-names>I.M.</given-names></name><name><surname>Zhang</surname><given-names>S.Y.</given-names></name><name><surname>Ciancanelli</surname><given-names>M.J.</given-names></name><name><surname>Herman</surname><given-names>M.</given-names></name><name><surname>Abhyankar</surname><given-names>A.</given-names></name><name><surname>Ying</surname><given-names>S.W.</given-names></name><name><surname>Keros</surname><given-names>S.</given-names></name><name><surname>Goldstein</surname><given-names>P.A.</given-names></name><name><surname>Mostoslavsky</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells</article-title><source>Nature</source><year>2012</year><volume>491</volume><fpage>769</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1038/nature11583</pub-id><?supplied-pmid 23103873?><pub-id pub-id-type="pmid">23103873</pub-id></element-citation></ref><ref id="B104-pathogens-08-00168"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez de Diego</surname><given-names>R.</given-names></name><name><surname>Sancho-Shimizu</surname><given-names>V.</given-names></name><name><surname>Lorenzo</surname><given-names>L.</given-names></name><name><surname>Puel</surname><given-names>A.</given-names></name><name><surname>Plancoulaine</surname><given-names>S.</given-names></name><name><surname>Picard</surname><given-names>C.</given-names></name><name><surname>Herman</surname><given-names>M.</given-names></name><name><surname>Cardon</surname><given-names>A.</given-names></name><name><surname>Durandy</surname><given-names>A.</given-names></name><name><surname>Bustamante</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.08.014</pub-id><?supplied-pmid 20832341?><pub-id pub-id-type="pmid">20832341</pub-id></element-citation></ref><ref id="B105-pathogens-08-00168"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancho-Shimizu</surname><given-names>V.</given-names></name><name><surname>Perez de Diego</surname><given-names>R.</given-names></name><name><surname>Lorenzo</surname><given-names>L.</given-names></name><name><surname>Halwani</surname><given-names>R.</given-names></name><name><surname>Alangari</surname><given-names>A.</given-names></name><name><surname>Israelsson</surname><given-names>E.</given-names></name><name><surname>Fabrega</surname><given-names>S.</given-names></name><name><surname>Cardon</surname><given-names>A.</given-names></name><name><surname>Maluenda</surname><given-names>J.</given-names></name><name><surname>Tatematsu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency</article-title><source>J. Clin. Investig.</source><year>2011</year><volume>121</volume><fpage>4889</fpage><lpage>4902</lpage><pub-id pub-id-type="doi">10.1172/JCI59259</pub-id><?supplied-pmid 22105173?><pub-id pub-id-type="pmid">22105173</pub-id></element-citation></ref><ref id="B106-pathogens-08-00168"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>M.</given-names></name><name><surname>Ciancanelli</surname><given-names>M.</given-names></name><name><surname>Ou</surname><given-names>Y.H.</given-names></name><name><surname>Lorenzo</surname><given-names>L.</given-names></name><name><surname>Klaudel-Dreszler</surname><given-names>M.</given-names></name><name><surname>Pauwels</surname><given-names>E.</given-names></name><name><surname>Sancho-Shimizu</surname><given-names>V.</given-names></name><name><surname>Perez de Diego</surname><given-names>R.</given-names></name><name><surname>Abhyankar</surname><given-names>A.</given-names></name><name><surname>Israelsson</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood</article-title><source>J. Exp. Med.</source><year>2012</year><volume>209</volume><fpage>1567</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1084/jem.20111316</pub-id><pub-id pub-id-type="pmid">22851595</pub-id></element-citation></ref><ref id="B107-pathogens-08-00168"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Anazi</surname><given-names>M.R.</given-names></name><name><surname>Matou-Nasri</surname><given-names>S.</given-names></name><name><surname>Abdo</surname><given-names>A.A.</given-names></name><name><surname>Sanai</surname><given-names>F.M.</given-names></name><name><surname>Alkahtani</surname><given-names>S.</given-names></name><name><surname>Alarifi</surname><given-names>S.</given-names></name><name><surname>Alkahtane</surname><given-names>A.A.</given-names></name><name><surname>Al-Yahya</surname><given-names>H.</given-names></name><name><surname>Ali</surname><given-names>D.</given-names></name><name><surname>Alessia</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection</article-title><source>J. Immunol. Res.</source><year>2017</year><volume>2017</volume><fpage>1590653</fpage><pub-id pub-id-type="doi">10.1155/2017/1590653</pub-id><pub-id pub-id-type="pmid">28127569</pub-id></element-citation></ref><ref id="B108-pathogens-08-00168"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Qahtani</surname><given-names>A.</given-names></name><name><surname>Al-Ahdal</surname><given-names>M.</given-names></name><name><surname>Abdo</surname><given-names>A.</given-names></name><name><surname>Sanai</surname><given-names>F.</given-names></name><name><surname>Al-Anazi</surname><given-names>M.</given-names></name><name><surname>Khalaf</surname><given-names>N.</given-names></name><name><surname>Viswan</surname><given-names>N.A.</given-names></name><name><surname>Al-Ashgar</surname><given-names>H.</given-names></name><name><surname>Al-Humaidan</surname><given-names>H.</given-names></name><name><surname>Al-Suwayeh</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients</article-title><source>J. Med. Virol.</source><year>2012</year><volume>84</volume><fpage>1353</fpage><lpage>1359</lpage><pub-id pub-id-type="doi">10.1002/jmv.23271</pub-id><pub-id pub-id-type="pmid">22825813</pub-id></element-citation></ref><ref id="B109-pathogens-08-00168"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>S.E.</given-names></name><name><surname>Christiansen</surname><given-names>M.</given-names></name><name><surname>Ryo</surname><given-names>L.B.</given-names></name><name><surname>Gad</surname><given-names>H.H.</given-names></name><name><surname>Gjedsted</surname><given-names>J.</given-names></name><name><surname>Staeheli</surname><given-names>P.</given-names></name><name><surname>Mikkelsen</surname><given-names>J.G.</given-names></name><name><surname>Storgaard</surname><given-names>M.</given-names></name><name><surname>Hartmann</surname><given-names>R.</given-names></name><name><surname>Mogensen</surname><given-names>T.H.</given-names></name></person-group><article-title>Defective RNA sensing by RIG-I in severe influenza virus infection</article-title><source>Clin. Exp. Immunol.</source><year>2018</year><volume>192</volume><fpage>366</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1111/cei.13120</pub-id><pub-id pub-id-type="pmid">29453856</pub-id></element-citation></ref><ref id="B110-pathogens-08-00168"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K.</given-names></name><name><surname>Yanai</surname><given-names>H.</given-names></name><name><surname>Negishi</surname><given-names>H.</given-names></name><name><surname>Asagiri</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Mizutani</surname><given-names>T.</given-names></name><name><surname>Shimada</surname><given-names>N.</given-names></name><name><surname>Ohba</surname><given-names>Y.</given-names></name><name><surname>Takaoka</surname><given-names>A.</given-names></name><name><surname>Yoshida</surname><given-names>N.</given-names></name><etal/></person-group><article-title>IRF-7 is the master regulator of type-I interferon-dependent immune responses</article-title><source>Nature</source><year>2005</year><volume>434</volume><fpage>772</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/nature03464</pub-id><pub-id pub-id-type="pmid">15800576</pub-id></element-citation></ref><ref id="B111-pathogens-08-00168"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marie</surname><given-names>I.</given-names></name><name><surname>Durbin</surname><given-names>J.E.</given-names></name><name><surname>Levy</surname><given-names>D.E.</given-names></name></person-group><article-title>Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7</article-title><source>EMBO J.</source><year>1998</year><volume>17</volume><fpage>6660</fpage><lpage>6669</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.22.6660</pub-id><?supplied-pmid 9822609?><pub-id pub-id-type="pmid">9822609</pub-id></element-citation></ref><ref id="B112-pathogens-08-00168"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterlund</surname><given-names>P.I.</given-names></name><name><surname>Pietila</surname><given-names>T.E.</given-names></name><name><surname>Veckman</surname><given-names>V.</given-names></name><name><surname>Kotenko</surname><given-names>S.V.</given-names></name><name><surname>Julkunen</surname><given-names>I.</given-names></name></person-group><article-title>IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes</article-title><source>J. Immunol.</source><year>2007</year><volume>179</volume><fpage>3434</fpage><lpage>3442</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.6.3434</pub-id><?supplied-pmid 17785777?><pub-id pub-id-type="pmid">17785777</pub-id></element-citation></ref><ref id="B113-pathogens-08-00168"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciancanelli</surname><given-names>M.J.</given-names></name><name><surname>Huang</surname><given-names>S.X.</given-names></name><name><surname>Luthra</surname><given-names>P.</given-names></name><name><surname>Garner</surname><given-names>H.</given-names></name><name><surname>Itan</surname><given-names>Y.</given-names></name><name><surname>Volpi</surname><given-names>S.</given-names></name><name><surname>Lafaille</surname><given-names>F.G.</given-names></name><name><surname>Trouillet</surname><given-names>C.</given-names></name><name><surname>Schmolke</surname><given-names>M.</given-names></name><name><surname>Albrecht</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1578</pub-id><?supplied-pmid 25814066?><pub-id pub-id-type="pmid">25814066</pub-id></element-citation></ref><ref id="B114-pathogens-08-00168"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Lindsay</surname><given-names>R.J.</given-names></name><name><surname>Kulkarni</surname><given-names>S.</given-names></name><name><surname>Lifson</surname><given-names>J.D.</given-names></name><name><surname>Carrington</surname><given-names>M.</given-names></name><name><surname>Altfeld</surname><given-names>M.</given-names></name></person-group><article-title>Polymorphisms in interferon regulatory factor 7 reduce interferon-alpha responses of plasmacytoid dendritic cells to HIV-1</article-title><source>AIDS</source><year>2011</year><volume>25</volume><fpage>715</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328343c186</pub-id><?supplied-pmid 21297422?><pub-id pub-id-type="pmid">21297422</pub-id></element-citation></ref><ref id="B115-pathogens-08-00168"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>N.</given-names></name><name><surname>Melki</surname><given-names>I.</given-names></name><name><surname>Jing</surname><given-names>H.</given-names></name><name><surname>Habib</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>S.S.Y.</given-names></name><name><surname>Danielson</surname><given-names>J.</given-names></name><name><surname>Kula</surname><given-names>T.</given-names></name><name><surname>Drutman</surname><given-names>S.</given-names></name><name><surname>Belkaya</surname><given-names>S.</given-names></name><name><surname>Rattina</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency</article-title><source>J. Exp. Med.</source><year>2018</year><volume>215</volume><fpage>2567</fpage><lpage>2585</lpage><pub-id pub-id-type="doi">10.1084/jem.20180628</pub-id><pub-id pub-id-type="pmid">30143481</pub-id></element-citation></ref><ref id="B116-pathogens-08-00168"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravo Garcia-Morato</surname><given-names>M.</given-names></name><name><surname>Calvo Apalategi</surname><given-names>A.</given-names></name><name><surname>Bravo-Gallego</surname><given-names>L.Y.</given-names></name><name><surname>Blazquez Moreno</surname><given-names>A.</given-names></name><name><surname>Simon-Fuentes</surname><given-names>M.</given-names></name><name><surname>Garmendia</surname><given-names>J.V.</given-names></name><name><surname>Mendez Echevarria</surname><given-names>A.</given-names></name><name><surname>Del Rosal Rabes</surname><given-names>T.</given-names></name><name><surname>Dominguez-Soto</surname><given-names>A.</given-names></name><name><surname>Lopez-Granados</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Impaired control of multiple viral infections in a family with complete IRF9 deficiency</article-title><source>J. Allergy Clin. Immunol.</source><year>2019</year><volume>144</volume><fpage>309</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.02.019</pub-id><?supplied-pmid 30826365?><pub-id pub-id-type="pmid">30826365</pub-id></element-citation></ref><ref id="B117-pathogens-08-00168"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakim</surname><given-names>L.M.</given-names></name><name><surname>Gupta</surname><given-names>N.</given-names></name><name><surname>Mintern</surname><given-names>J.D.</given-names></name><name><surname>Villadangos</surname><given-names>J.A.</given-names></name></person-group><article-title>Enhanced survival of lung tissue-resident memory CD8(+) T cells during infection with influenza virus due to selective expression of IFITM3</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>238</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/ni.2525</pub-id><pub-id pub-id-type="pmid">23354485</pub-id></element-citation></ref><ref id="B118-pathogens-08-00168"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everitt</surname><given-names>A.R.</given-names></name><name><surname>Clare</surname><given-names>S.</given-names></name><name><surname>Pertel</surname><given-names>T.</given-names></name><name><surname>John</surname><given-names>S.P.</given-names></name><name><surname>Wash</surname><given-names>R.S.</given-names></name><name><surname>Smith</surname><given-names>S.E.</given-names></name><name><surname>Chin</surname><given-names>C.R.</given-names></name><name><surname>Feeley</surname><given-names>E.M.</given-names></name><name><surname>Sims</surname><given-names>J.S.</given-names></name><name><surname>Adams</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>IFITM3 restricts the morbidity and mortality associated with influenza</article-title><source>Nature</source><year>2012</year><volume>484</volume><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1038/nature10921</pub-id><pub-id pub-id-type="pmid">22446628</pub-id></element-citation></ref><ref id="B119-pathogens-08-00168"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>J.M.</given-names></name><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Pan</surname><given-names>X.B.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Block</surname><given-names>T.M.</given-names></name><name><surname>Guo</surname><given-names>J.T.</given-names></name></person-group><article-title>Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>12646</fpage><lpage>12657</lpage><pub-id pub-id-type="doi">10.1128/JVI.01328-10</pub-id><pub-id pub-id-type="pmid">20943977</pub-id></element-citation></ref><ref id="B120-pathogens-08-00168"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.H.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Peng</surname><given-names>Y.C.</given-names></name><name><surname>Giannoulatou</surname><given-names>E.</given-names></name><name><surname>Jin</surname><given-names>R.H.</given-names></name><name><surname>Yan</surname><given-names>H.P.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.H.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals</article-title><source>Nat. Commun.</source><year>2013</year><volume>4</volume><fpage>1418</fpage><pub-id pub-id-type="doi">10.1038/ncomms2433</pub-id><pub-id pub-id-type="pmid">23361009</pub-id></element-citation></ref><ref id="B121-pathogens-08-00168"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Tan</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Shao</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Interferon-Inducible Transmembrane Protein 3 Genetic Variant rs12252 and Influenza Susceptibility and Severity: A Meta-Analysis</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0124985</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0124985</pub-id><?supplied-pmid 25942469?><pub-id pub-id-type="pmid">25942469</pub-id></element-citation></ref><ref id="B122-pathogens-08-00168"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhu</surname><given-names>S.S.</given-names></name><name><surname>Chakraborty</surname><given-names>T.T.</given-names></name><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Banerjee</surname><given-names>I.</given-names></name></person-group><article-title>Association between IFITM3 rs12252 polymorphism and influenza susceptibility and severity: A meta-analysis</article-title><source>Gene</source><year>2018</year><volume>674</volume><fpage>70</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2018.06.070</pub-id><?supplied-pmid 29940276?><pub-id pub-id-type="pmid">29940276</pub-id></element-citation></ref><ref id="B123-pathogens-08-00168"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>E.K.</given-names></name><name><surname>Randolph</surname><given-names>A.G.</given-names></name><name><surname>Bhangale</surname><given-names>T.</given-names></name><name><surname>Dogra</surname><given-names>P.</given-names></name><name><surname>Ohlson</surname><given-names>M.</given-names></name><name><surname>Oshansky</surname><given-names>C.M.</given-names></name><name><surname>Zamora</surname><given-names>A.E.</given-names></name><name><surname>Shannon</surname><given-names>J.P.</given-names></name><name><surname>Finkelstein</surname><given-names>D.</given-names></name><name><surname>Dressen</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>975</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1038/nm.4370</pub-id><pub-id pub-id-type="pmid">28714988</pub-id></element-citation></ref><ref id="B124-pathogens-08-00168"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisfeld</surname><given-names>A.J.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group><article-title>Calculated risk: A new single-nucleotide polymorphism linked to severe influenza disease</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>911</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1038/nm.4383</pub-id><?supplied-pmid 28777788?><pub-id pub-id-type="pmid">28777788</pub-id></element-citation></ref><ref id="B125-pathogens-08-00168"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>C.A.</given-names></name></person-group><article-title>IL-1: Discoveries, controversies and future directions</article-title><source>Eur. J. Immunol.</source><year>2010</year><volume>40</volume><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1002/eji.201040319</pub-id><pub-id pub-id-type="pmid">20201008</pub-id></element-citation></ref><ref id="B126-pathogens-08-00168"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Nie</surname><given-names>G.</given-names></name><name><surname>Meng</surname><given-names>Z.</given-names></name><name><surname>Mao</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Zeng</surname><given-names>G.</given-names></name></person-group><article-title>Genetic variants in IL1A and IL1B contribute to the susceptibility to 2009 pandemic H1N1 influenza A virus</article-title><source>BMC Immunol.</source><year>2013</year><volume>14</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2172-14-37</pub-id><pub-id pub-id-type="pmid">23927441</pub-id></element-citation></ref><ref id="B127-pathogens-08-00168"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yue</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name><name><surname>Zhan</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Liao</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Allele-specific induction of IL-1beta expression by C/EBPbeta and PU.1 contributes to increased tuberculosis susceptibility</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><elocation-id>e1004426</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004426</pub-id><pub-id pub-id-type="pmid">25329476</pub-id></element-citation></ref><ref id="B128-pathogens-08-00168"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>H.</given-names></name><name><surname>Haugen</surname><given-names>A.</given-names></name><name><surname>Zienolddiny</surname><given-names>S.</given-names></name></person-group><article-title>Differential binding of proteins to the IL1B -31 T/C polymorphism in lung epithelial cells</article-title><source>Cytokine</source><year>2007</year><volume>38</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2007.05.001</pub-id><pub-id pub-id-type="pmid">17587593</pub-id></element-citation></ref><ref id="B129-pathogens-08-00168"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luft</surname><given-names>T.</given-names></name><name><surname>Jefford</surname><given-names>M.</given-names></name><name><surname>Luetjens</surname><given-names>P.</given-names></name><name><surname>Hochrein</surname><given-names>H.</given-names></name><name><surname>Masterman</surname><given-names>K.A.</given-names></name><name><surname>Maliszewski</surname><given-names>C.</given-names></name><name><surname>Shortman</surname><given-names>K.</given-names></name><name><surname>Cebon</surname><given-names>J.</given-names></name><name><surname>Maraskovsky</surname><given-names>E.</given-names></name></person-group><article-title>IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): A mechanism for T cell-independent DC activation</article-title><source>J. Immunol.</source><year>2002</year><volume>168</volume><fpage>713</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.2.713</pub-id><pub-id pub-id-type="pmid">11777965</pub-id></element-citation></ref><ref id="B130-pathogens-08-00168"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonopoulou</surname><given-names>A.</given-names></name><name><surname>Baziaka</surname><given-names>F.</given-names></name><name><surname>Tsaganos</surname><given-names>T.</given-names></name><name><surname>Raftogiannis</surname><given-names>M.</given-names></name><name><surname>Koutoukas</surname><given-names>P.</given-names></name><name><surname>Spyridaki</surname><given-names>A.</given-names></name><name><surname>Mouktaroudi</surname><given-names>M.</given-names></name><name><surname>Kotsaki</surname><given-names>A.</given-names></name><name><surname>Savva</surname><given-names>A.</given-names></name><name><surname>Georgitsi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Role of tumor necrosis factor gene single nucleotide polymorphisms in the natural course of 2009 influenza A H1N1 virus infection</article-title><source>Int. J. Infect. Dis.</source><year>2012</year><volume>16</volume><fpage>e204</fpage><lpage>e208</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2011.11.012</pub-id><pub-id pub-id-type="pmid">22269998</pub-id></element-citation></ref><ref id="B131-pathogens-08-00168"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Ramirez</surname><given-names>R.A.</given-names></name><name><surname>Ramirez-Venegas</surname><given-names>A.</given-names></name><name><surname>Quintana-Carrillo</surname><given-names>R.</given-names></name><name><surname>Camarena</surname><given-names>A.E.</given-names></name><name><surname>Falfan-Valencia</surname><given-names>R.</given-names></name><name><surname>Mejia-Arangure</surname><given-names>J.M.</given-names></name></person-group><article-title>TNF, IL6, and IL1B Polymorphisms Are Associated with Severe Influenza A (H1N1) Virus Infection in the Mexican Population</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0144832</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0144832</pub-id><?supplied-pmid 26657940?><pub-id pub-id-type="pmid">26657940</pub-id></element-citation></ref><ref id="B132-pathogens-08-00168"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deval</surname><given-names>H.</given-names></name><name><surname>Alagarasu</surname><given-names>K.</given-names></name><name><surname>Mittal</surname><given-names>M.</given-names></name><name><surname>Srivastava</surname><given-names>N.</given-names></name><name><surname>Bachal</surname><given-names>R.</given-names></name><name><surname>Gondhalekar</surname><given-names>A.</given-names></name><name><surname>Chaudhary</surname><given-names>U.</given-names></name><name><surname>Chowdhary</surname><given-names>D.</given-names></name><name><surname>Bondre</surname><given-names>V.P.</given-names></name></person-group><article-title>Association of single nucleotide polymorphisms in TNFA and CCR5 genes with Japanese Encephalitis: A study from an endemic region of North India</article-title><source>J. Neuroimmunol.</source><year>2019</year><volume>336</volume><fpage>577043</fpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2019.577043</pub-id><?supplied-pmid 31479868?><pub-id pub-id-type="pmid">31479868</pub-id></element-citation></ref><ref id="B133-pathogens-08-00168"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Consortium</surname><given-names>H.B.V.S.</given-names></name></person-group><article-title>A study of TNF-alpha-238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China</article-title><source>Pathology</source><year>2010</year><volume>42</volume><fpage>674</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.3109/00313025.2010.523696</pub-id><?supplied-pmid 21080879?><pub-id pub-id-type="pmid">21080879</pub-id></element-citation></ref><ref id="B134-pathogens-08-00168"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>W.G.</given-names></name><name><surname>McDermott</surname><given-names>D.H.</given-names></name><name><surname>Lim</surname><given-names>J.K.</given-names></name><name><surname>Lekhong</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>S.F.</given-names></name><name><surname>Frank</surname><given-names>W.A.</given-names></name><name><surname>Pape</surname><given-names>J.</given-names></name><name><surname>Cheshier</surname><given-names>R.C.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>CCR5 deficiency increases risk of symptomatic West Nile virus infection</article-title><source>J. Exp. Med.</source><year>2006</year><volume>203</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1084/jem.20051970</pub-id><?supplied-pmid 16418398?><pub-id pub-id-type="pmid">16418398</pub-id></element-citation></ref><ref id="B135-pathogens-08-00168"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keynan</surname><given-names>Y.</given-names></name><name><surname>Juno</surname><given-names>J.</given-names></name><name><surname>Meyers</surname><given-names>A.</given-names></name><name><surname>Ball</surname><given-names>T.B.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Rubinstein</surname><given-names>E.</given-names></name><name><surname>Fowke</surname><given-names>K.R.</given-names></name></person-group><article-title>Chemokine receptor 5 big up tri, open32 allele in patients with severe pandemic (H1N1) 2009</article-title><source>Emerg. Infect. Dis.</source><year>2010</year><volume>16</volume><fpage>1621</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.3201/eid1610.100108</pub-id><?supplied-pmid 20875295?><pub-id pub-id-type="pmid">20875295</pub-id></element-citation></ref><ref id="B136-pathogens-08-00168"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samson</surname><given-names>M.</given-names></name><name><surname>Libert</surname><given-names>F.</given-names></name><name><surname>Doranz</surname><given-names>B.J.</given-names></name><name><surname>Rucker</surname><given-names>J.</given-names></name><name><surname>Liesnard</surname><given-names>C.</given-names></name><name><surname>Farber</surname><given-names>C.M.</given-names></name><name><surname>Saragosti</surname><given-names>S.</given-names></name><name><surname>Lapoumeroulie</surname><given-names>C.</given-names></name><name><surname>Cognaux</surname><given-names>J.</given-names></name><name><surname>Forceille</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene</article-title><source>Nature</source><year>1996</year><volume>382</volume><fpage>722</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1038/382722a0</pub-id><pub-id pub-id-type="pmid">8751444</pub-id></element-citation></ref><ref id="B137-pathogens-08-00168"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Z.S.</given-names></name><name><surname>Lau</surname><given-names>C.C.</given-names></name><name><surname>Poon</surname><given-names>V.K.</given-names></name><name><surname>Fan</surname><given-names>Y.H.</given-names></name><name><surname>Song</surname><given-names>Y.Q.</given-names></name><name><surname>Tse</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><etal/></person-group><article-title>A functional variation in CD55 increases the severity of 2009 pandemic H1N1 influenza A virus infection</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>206</volume><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis378</pub-id><?supplied-pmid 22693232?><pub-id pub-id-type="pmid">22693232</pub-id></element-citation></ref><ref id="B138-pathogens-08-00168"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatzopoulou</surname><given-names>F.</given-names></name><name><surname>Gioula</surname><given-names>G.</given-names></name><name><surname>Kioumis</surname><given-names>I.</given-names></name><name><surname>Chatzidimitriou</surname><given-names>D.</given-names></name><name><surname>Exindari</surname><given-names>M.</given-names></name></person-group><article-title>Identification of complement-related host genetic risk factors associated with influenza A(H1N1)pdm09 outcome: Challenges ahead</article-title><source>Med. Microbiol. Immunol.</source><year>2018</year><pub-id pub-id-type="doi">10.1007/s00430-018-0567-9</pub-id><?supplied-pmid 30306260?><pub-id pub-id-type="pmid">30306260</pub-id></element-citation></ref><ref id="B139-pathogens-08-00168"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewulonu</surname><given-names>U.K.</given-names></name><name><surname>Ravi</surname><given-names>L.</given-names></name><name><surname>Medof</surname><given-names>M.E.</given-names></name></person-group><article-title>Characterization of the decay-accelerating factor gene promoter region</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1991</year><volume>88</volume><fpage>4675</fpage><lpage>4679</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.11.4675</pub-id><pub-id pub-id-type="pmid">1711208</pub-id></element-citation></ref><ref id="B140-pathogens-08-00168"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuniga</surname><given-names>J.</given-names></name><name><surname>Buendia-Roldan</surname><given-names>I.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Jimenez</surname><given-names>L.</given-names></name><name><surname>Torres</surname><given-names>D.</given-names></name><name><surname>Romo</surname><given-names>J.</given-names></name><name><surname>Ramirez</surname><given-names>G.</given-names></name><name><surname>Cruz</surname><given-names>A.</given-names></name><name><surname>Vargas-Alarcon</surname><given-names>G.</given-names></name><name><surname>Sheu</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Genetic variants associated with severe pneumonia in A/H1N1 influenza infection</article-title><source>Eur. Respir J</source><year>2012</year><volume>39</volume><fpage>604</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1183/09031936.00020611</pub-id><?supplied-pmid 21737555?><pub-id pub-id-type="pmid">21737555</pub-id></element-citation></ref><ref id="B141-pathogens-08-00168"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>W.C.</given-names></name><name><surname>Tate</surname><given-names>M.D.</given-names></name><name><surname>Brooks</surname><given-names>A.G.</given-names></name><name><surname>Reading</surname><given-names>P.C.</given-names></name></person-group><article-title>Soluble host defense lectins in innate immunity to influenza virus</article-title><source>J Biomed Biotechnol</source><year>2012</year><volume>2012</volume><fpage>732191</fpage><pub-id pub-id-type="doi">10.1155/2012/732191</pub-id><pub-id pub-id-type="pmid">22665991</pub-id></element-citation></ref><ref id="B142-pathogens-08-00168"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeVine</surname><given-names>A.M.</given-names></name><name><surname>Hartshorn</surname><given-names>K.</given-names></name><name><surname>Elliott</surname><given-names>J.</given-names></name><name><surname>Whitsett</surname><given-names>J.</given-names></name><name><surname>Korfhagen</surname><given-names>T.</given-names></name></person-group><article-title>Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection</article-title><source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source><year>2002</year><volume>282</volume><fpage>L563</fpage><lpage>L572</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00280.2001</pub-id><pub-id pub-id-type="pmid">11839553</pub-id></element-citation></ref><ref id="B143-pathogens-08-00168"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Siddiqui</surname><given-names>J.</given-names></name><name><surname>Hendry</surname><given-names>M.</given-names></name><name><surname>Akiyama</surname><given-names>J.</given-names></name><name><surname>Edmondson</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>C.</given-names></name><name><surname>Allen</surname><given-names>L.</given-names></name><name><surname>Levitt</surname><given-names>S.</given-names></name><name><surname>Poulain</surname><given-names>F.</given-names></name><name><surname>Hawgood</surname><given-names>S.</given-names></name></person-group><article-title>Surfactant protein-A--deficient mice display an exaggerated early inflammatory response to a beta-resistant strain of influenza A virus</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2002</year><volume>26</volume><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1165/ajrcmb.26.3.4584</pub-id><pub-id pub-id-type="pmid">11867335</pub-id></element-citation></ref><ref id="B144-pathogens-08-00168"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartshorn</surname><given-names>K.L.</given-names></name><name><surname>White</surname><given-names>M.R.</given-names></name><name><surname>Shepherd</surname><given-names>V.</given-names></name><name><surname>Reid</surname><given-names>K.</given-names></name><name><surname>Jensenius</surname><given-names>J.C.</given-names></name><name><surname>Crouch</surname><given-names>E.C.</given-names></name></person-group><article-title>Mechanisms of anti-influenza activity of surfactant proteins A and D: Comparison with serum collectins</article-title><source>Am. J. Physiol.</source><year>1997</year><volume>273</volume><fpage>L1156</fpage><lpage>L1166</lpage><pub-id pub-id-type="doi">10.1152/ajplung.1997.273.6.L1156</pub-id><pub-id pub-id-type="pmid">9435570</pub-id></element-citation></ref><ref id="B145-pathogens-08-00168"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera-Ramos</surname><given-names>E.</given-names></name><name><surname>Lopez-Rodriguez</surname><given-names>M.</given-names></name><name><surname>Ruiz-Hernandez</surname><given-names>J.J.</given-names></name><name><surname>Horcajada</surname><given-names>J.P.</given-names></name><name><surname>Borderias</surname><given-names>L.</given-names></name><name><surname>Lerma</surname><given-names>E.</given-names></name><name><surname>Blanquer</surname><given-names>J.</given-names></name><name><surname>Perez-Gonzalez</surname><given-names>M.C.</given-names></name><name><surname>Garcia-Laorden</surname><given-names>M.I.</given-names></name><name><surname>Florido</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Surfactant protein A genetic variants associate with severe respiratory insufficiency in pandemic influenza A virus infection</article-title><source>Crit. Care</source><year>2014</year><volume>18</volume><fpage>R127</fpage><pub-id pub-id-type="doi">10.1186/cc13934</pub-id><pub-id pub-id-type="pmid">24950659</pub-id></element-citation></ref><ref id="B146-pathogens-08-00168"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M.L.</given-names></name><name><surname>Chen</surname><given-names>Y.H.</given-names></name><name><surname>Wang</surname><given-names>S.W.</given-names></name><name><surname>Huang</surname><given-names>Y.J.</given-names></name><name><surname>Leu</surname><given-names>C.H.</given-names></name><name><surname>Yeh</surname><given-names>N.C.</given-names></name><name><surname>Chu</surname><given-names>C.Y.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name><name><surname>Shieh</surname><given-names>G.S.</given-names></name><name><surname>Chen</surname><given-names>Y.L.</given-names></name><etal/></person-group><article-title>Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>10010</fpage><lpage>10020</lpage><pub-id pub-id-type="doi">10.1128/JVI.00301-11</pub-id><pub-id pub-id-type="pmid">21795357</pub-id></element-citation></ref><ref id="B147-pathogens-08-00168"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>B.H.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Functional variants regulating LGALS1 (Galectin 1) expression affect human susceptibility to influenza A(H7N9)</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>8517</fpage><pub-id pub-id-type="doi">10.1038/srep08517</pub-id><pub-id pub-id-type="pmid">25687228</pub-id></element-citation></ref><ref id="B148-pathogens-08-00168"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatesuer</surname><given-names>B.</given-names></name><name><surname>Bertram</surname><given-names>S.</given-names></name><name><surname>Mehnert</surname><given-names>N.</given-names></name><name><surname>Bahgat</surname><given-names>M.M.</given-names></name><name><surname>Nelson</surname><given-names>P.S.</given-names></name><name><surname>Pohlmann</surname><given-names>S.</given-names></name><name><surname>Schughart</surname><given-names>K.</given-names></name></person-group><article-title>Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003774</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003774</pub-id><pub-id pub-id-type="pmid">24348248</pub-id></element-citation></ref><ref id="B149-pathogens-08-00168"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Hao</surname><given-names>K.</given-names></name><name><surname>Bosse</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Identification of TMPRSS2 as a Susceptibility Gene for Severe 2009 Pandemic A(H1N1) Influenza and A(H7N9) Influenza</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>212</volume><fpage>1214</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv246</pub-id><pub-id pub-id-type="pmid">25904605</pub-id></element-citation></ref><ref id="B150-pathogens-08-00168"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoszko</surname><given-names>J.J.</given-names></name><name><surname>McNamara</surname><given-names>I.F.</given-names></name><name><surname>Aras</surname><given-names>O.A.Z.</given-names></name><name><surname>Hylton</surname><given-names>D.A.</given-names></name><name><surname>Zhang</surname><given-names>Y.B.</given-names></name><name><surname>Malhotra</surname><given-names>D.</given-names></name><name><surname>Hyett</surname><given-names>S.L.</given-names></name><name><surname>Morassut</surname><given-names>R.E.</given-names></name><name><surname>Rudziak</surname><given-names>P.</given-names></name><name><surname>Loeb</surname><given-names>M.</given-names></name></person-group><article-title>Does consecutive influenza vaccination reduce protection against influenza: A systematic review and meta-analysis</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>3434</fpage><lpage>3444</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.04.049</pub-id><pub-id pub-id-type="pmid">29724509</pub-id></element-citation></ref><ref id="B151-pathogens-08-00168"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belongia</surname><given-names>E.A.</given-names></name><name><surname>Skowronski</surname><given-names>D.M.</given-names></name><name><surname>McLean</surname><given-names>H.Q.</given-names></name><name><surname>Chambers</surname><given-names>C.</given-names></name><name><surname>Sundaram</surname><given-names>M.E.</given-names></name><name><surname>De Serres</surname><given-names>G.</given-names></name></person-group><article-title>Repeated annual influenza vaccination and vaccine effectiveness: Review of evidence</article-title><source>Expert Rev. Vaccines</source><year>2017</year><volume>16</volume><fpage>723</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1334554</pub-id></element-citation></ref><ref id="B152-pathogens-08-00168"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leidner</surname><given-names>A.J.</given-names></name><name><surname>Murthy</surname><given-names>N.</given-names></name><name><surname>Chesson</surname><given-names>H.W.</given-names></name><name><surname>Biggerstaff</surname><given-names>M.</given-names></name><name><surname>Stoecker</surname><given-names>C.</given-names></name><name><surname>Harris</surname><given-names>A.M.</given-names></name><name><surname>Acosta</surname><given-names>A.</given-names></name><name><surname>Dooling</surname><given-names>K.</given-names></name><name><surname>Bridges</surname><given-names>C.B.</given-names></name></person-group><article-title>Cost-effectiveness of adult vaccinations: A systematic review</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>226</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.11.056</pub-id><pub-id pub-id-type="pmid">30527660</pub-id></element-citation></ref><ref id="B153-pathogens-08-00168"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egli</surname><given-names>A.</given-names></name><name><surname>Santer</surname><given-names>D.M.</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>D.</given-names></name><name><surname>Barakat</surname><given-names>K.</given-names></name><name><surname>Syedbasha</surname><given-names>M.</given-names></name><name><surname>Vollmer</surname><given-names>M.</given-names></name><name><surname>Baluch</surname><given-names>A.</given-names></name><name><surname>Bhat</surname><given-names>R.</given-names></name><name><surname>Groenendyk</surname><given-names>J.</given-names></name><name><surname>Joyce</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>IL-28B is a key regulator of B- and T-cell vaccine responses against influenza</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><elocation-id>e1004556</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004556</pub-id><pub-id pub-id-type="pmid">25503988</pub-id></element-citation></ref><ref id="B154-pathogens-08-00168"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelder</surname><given-names>C.M.</given-names></name><name><surname>Lambkin</surname><given-names>R.</given-names></name><name><surname>Hart</surname><given-names>K.W.</given-names></name><name><surname>Fleming</surname><given-names>D.</given-names></name><name><surname>Williams</surname><given-names>O.M.</given-names></name><name><surname>Bunce</surname><given-names>M.</given-names></name><name><surname>Welsh</surname><given-names>K.I.</given-names></name><name><surname>Marshall</surname><given-names>S.E.</given-names></name><name><surname>Oxford</surname><given-names>J.</given-names></name></person-group><article-title>Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine</article-title><source>J. Infect. Dis.</source><year>2002</year><volume>185</volume><fpage>114</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1086/338014</pub-id><pub-id pub-id-type="pmid">11756990</pub-id></element-citation></ref><ref id="B155-pathogens-08-00168"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linnik</surname><given-names>J.E.</given-names></name><name><surname>Egli</surname><given-names>A.</given-names></name></person-group><article-title>Impact of host genetic polymorphisms on vaccine induced antibody response</article-title><source>Hum. Vaccin Immunother.</source><year>2016</year><volume>12</volume><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1119345</pub-id><pub-id pub-id-type="pmid">26809773</pub-id></element-citation></ref><ref id="B156-pathogens-08-00168"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poland</surname><given-names>G.A.</given-names></name><name><surname>Ovsyannikova</surname><given-names>I.G.</given-names></name><name><surname>Jacobson</surname><given-names>R.M.</given-names></name></person-group><article-title>Immunogenetics of seasonal influenza vaccine response</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>D35</fpage><lpage>D40</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.065</pub-id><pub-id pub-id-type="pmid">19230157</pub-id></element-citation></ref><ref id="B157-pathogens-08-00168"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burleson</surname><given-names>G.R.</given-names></name></person-group><article-title>Immunological Variation Due to Genetics of Inflammatory SNPs and Age and Impact on Disease Manifestation</article-title><source>Toxicol. Pathol.</source><year>2017</year><volume>45</volume><fpage>146</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1177/0192623316677070</pub-id><pub-id pub-id-type="pmid">28068891</pub-id></element-citation></ref><ref id="B158-pathogens-08-00168"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castiblanco</surname><given-names>J.</given-names></name><name><surname>Anaya</surname><given-names>J.M.</given-names></name></person-group><article-title>Genetics and vaccines in the era of personalized medicine</article-title><source>Curr. Genom.</source><year>2015</year><volume>16</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.2174/1389202916666141223220551</pub-id></element-citation></ref><ref id="B159-pathogens-08-00168"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Host genetic factors can impact vaccine immunogenicity and effectiveness</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>359</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30121-5</pub-id><pub-id pub-id-type="pmid">30938297</pub-id></element-citation></ref><ref id="B160-pathogens-08-00168"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>M.</given-names></name><name><surname>Nourishirazi</surname><given-names>E.</given-names></name><name><surname>Guinet</surname><given-names>E.</given-names></name><name><surname>Nouri-Shirazi</surname><given-names>M.</given-names></name></person-group><article-title>The genetic background influences the cellular and humoral immune responses to vaccines</article-title><source>Clin. Exp. Immunol.</source><year>2016</year><volume>186</volume><fpage>190</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1111/cei.12841</pub-id><pub-id pub-id-type="pmid">27393001</pub-id></element-citation></ref><ref id="B161-pathogens-08-00168"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allcock</surname><given-names>R.J.</given-names></name></person-group><article-title>The major histocompatibility complex: A paradigm for studies of the human genome</article-title><source>Methods Mol. Biol.</source><year>2012</year><volume>882</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-842-9_1</pub-id><?supplied-pmid 22665225?><pub-id pub-id-type="pmid">22665225</pub-id></element-citation></ref><ref id="B162-pathogens-08-00168"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apanius</surname><given-names>V.</given-names></name><name><surname>Penn</surname><given-names>D.</given-names></name><name><surname>Slev</surname><given-names>P.R.</given-names></name><name><surname>Ruff</surname><given-names>L.R.</given-names></name><name><surname>Potts</surname><given-names>W.K.</given-names></name></person-group><article-title>The Nature of Selection on the Major Histocompatibility Complex</article-title><source>Crit. Rev. Immunol.</source><year>2017</year><volume>37</volume><fpage>75</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1615/CritRevImmunol.v37.i2-6.10</pub-id><?supplied-pmid 29773018?><pub-id pub-id-type="pmid">29773018</pub-id></element-citation></ref><ref id="B163-pathogens-08-00168"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garred</surname><given-names>P.</given-names></name><name><surname>Genster</surname><given-names>N.</given-names></name><name><surname>Pilely</surname><given-names>K.</given-names></name><name><surname>Bayarri-Olmos</surname><given-names>R.</given-names></name><name><surname>Rosbjerg</surname><given-names>A.</given-names></name><name><surname>Ma</surname><given-names>Y.J.</given-names></name><name><surname>Skjoedt</surname><given-names>M.O.</given-names></name></person-group><article-title>A journey through the lectin pathway of complement-MBL and beyond</article-title><source>Immunol. Rev.</source><year>2016</year><volume>274</volume><fpage>74</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/imr.12468</pub-id><?supplied-pmid 27782323?><pub-id pub-id-type="pmid">27782323</pub-id></element-citation></ref><ref id="B164-pathogens-08-00168"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>M.W.</given-names></name></person-group><article-title>The role of mannose-binding lectin in health and disease</article-title><source>Mol. Immunol.</source><year>2003</year><volume>40</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/S0161-5890(03)00155-X</pub-id><pub-id pub-id-type="pmid">14568388</pub-id></element-citation></ref><ref id="B165-pathogens-08-00168"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y.W.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Shyr</surname><given-names>Y.</given-names></name><name><surname>Edwards</surname><given-names>K.M.</given-names></name></person-group><article-title>Host single-nucleotide polymorphisms and altered responses to inactivated influenza vaccine</article-title><source>J. Infect. Dis.</source><year>2007</year><volume>196</volume><fpage>1021</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1086/521370</pub-id><?supplied-pmid 17763324?><pub-id pub-id-type="pmid">17763324</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pathogens-08-00168-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Influenza A virus structure and genome organization. (<bold>A</bold>) Virion structure: Influenza A viruses include a lipid envelope containing the two viral glycoproteins (HA, green and NA, purple). The ion channel M2 (red) protein is also located in the membrane. Under the viral bilayer is located a protein layer composed of the M1 (light blue) protein, and the NEP (yellow). Inside the virion are located the eight vRNA segments coated by the NP (pink) as viral vRNP complexes and associated with the viral polymerase complex made of the three polymerase subunits PB2 (red), PB1 (blue) and PA (gray). Viral components in the vRNP and in the viral particle are indicated. (<bold>B</bold>) Genome organization: Influenza A virus contains eight ss, negative-sense, viral RNA segments (PB2, PB1, PA, HA, NP, NA, M, and NS). Each viral segment contains non-coding regions (NCR, black) and the packaging signals (PKS, gray) at the 3&#x02032; and 5&#x02032; termini in each of the viral segments.</p></caption><graphic xlink:href="pathogens-08-00168-g001"/></fig><fig id="pathogens-08-00168-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><bold>Single nucleotide polymorphisms (SNPs).</bold> (<bold>A</bold>) An SNP is a variation on a single nucleotide which may occur at some specific point in the genome and that causes variations in DNA sequences between members of the same species. (<bold>B</bold>) Types of SNPs: DNA variation can be located in non-coding or coding regions. SNPs within a coding sequence can be synonymous if they do not produce an amino acid change (silent mutation), or non-synonymous if they affect the protein sequence. Non-synonymous changes can be divided into missense (producing an amino acid change in the protein) or nonsense (producing a truncated or longer protein).</p></caption><graphic xlink:href="pathogens-08-00168-g002"/></fig><table-wrap id="pathogens-08-00168-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pathogens-08-00168-t001_Table 1</object-id><label>Table 1</label><caption><p>Single nucleotide polymorphisms associated with susceptibility and severity of influenza infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SNPs (Type)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recognizes dsRNA, triggering IFN production.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs not annotated; F303S (NonSyn).<break/>rs5743313 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-pathogens-08-00168" ref-type="bibr">98</xref>]<break/>[<xref rid="B99-pathogens-08-00168" ref-type="bibr">99</xref>,<xref rid="B100-pathogens-08-00168" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RIG-I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detects dsRNA and 5&#x02032;- triphosphates of the negative ssRNA IAV genome, leading to innate immune responses activation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs72710678; R71H (NonSyn).<break/>rs138425677; P885S (NonSyn).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-pathogens-08-00168" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IRF-7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transcription factor that increases IFN production in response to viruses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs786205223; F410V (NonSyn)<break/>rs375323253; Q421X (NonSyn)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-pathogens-08-00168" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IRF-9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transcription factor essential for IFN signaling and the transcriptional induction of ISGs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.991G&#x0003e;A occurred in the final nucleotide of exon 7 and disrupted the essential splice site at the boundary of exon 7 and intron 7 (NonSyn).<break/>c.577+1G&#x0003e;T, was localized in the donor splice site of introns 5 and 6 and led to transcripts lacking exon 5 (NonSyn).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-pathogens-08-00168" ref-type="bibr">115</xref>]<break/><break/><break/><break/><break/>[<xref rid="B116-pathogens-08-00168" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFITM3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ISG which abrogates the release of IAV content from late endosomes into the cytoplasm. IFITM3 increases the survival of mouse lung-resident CD8<sup>+</sup> T cells after IAV infection, which can help clear the infection.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs12252, leading to an alteration of the first splice acceptor site, leading to an IFITM3 protein lacking the first 21 amino acids (NonSyn).<break/>rs34481144, is located in the 5&#x02032;-UTR and affects IFITM3 expression with the risk allele showing lower mRNA expression (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-pathogens-08-00168" ref-type="bibr">100</xref>,<xref rid="B118-pathogens-08-00168" ref-type="bibr">118</xref>,<xref rid="B120-pathogens-08-00168" ref-type="bibr">120</xref>,<xref rid="B122-pathogens-08-00168" ref-type="bibr">122</xref>]<break/><break/><break/>[<xref rid="B123-pathogens-08-00168" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-1B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammatory cytokine involved in the development of adaptive immune responses. Furthermore, accumulating data has suggested that IL-1A and IL-1B have critical roles in innate immunity against viral infections.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs1143627, located 31 base pairs upstream from the transcription start site, on the IL-1B promoter. This nucleotide change is located in a TATA-box motif of IL-1B, affecting the transcription activity of IL-1B (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B128-pathogens-08-00168" ref-type="bibr">128</xref>,<xref rid="B129-pathogens-08-00168" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-1A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammatory cytokine that plays important roles in the development of adaptive immune responses. Moreover, multiple pieces of evidence have suggested that IL-1A and IL-1B play relevant roles in innate immunity against viral infections.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs17561; A114S (NonSyn).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B126-pathogens-08-00168" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pro-inflammatory cytokine which orchestrates the host&#x000b4;s defense.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs361525, a minor allele (A) at position 238 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-pathogens-08-00168" ref-type="bibr">92</xref>,<xref rid="B130-pathogens-08-00168" ref-type="bibr">130</xref>,<xref rid="B131-pathogens-08-00168" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCR5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine receptor which has a role in mediating leukocyte migration in response to its ligands, including MIP-1a, MIP-1b, and RANTES. Furthermore, it can help direct many immune cell subsets, including regulatory T cells and Th17 cells to sites of infection, supporting the antiviral immune response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCR5-&#x00394;32 allele (NonSyn).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-pathogens-08-00168" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blocks C3 and C5 activation by inhibiting the formation of new C3 and C5 convertases, which are two proteases involved in complement activation and inflammation. CD55 functions to protect cells from complement attack and decreases the amplification of the complement cascade</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs2564978, resides in the minimal promoter region, affecting gene expression (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-pathogens-08-00168" ref-type="bibr">47</xref>,<xref rid="B79-pathogens-08-00168" ref-type="bibr">79</xref>,<xref rid="B100-pathogens-08-00168" ref-type="bibr">100</xref>,<xref rid="B137-pathogens-08-00168" ref-type="bibr">137</xref>,<xref rid="B138-pathogens-08-00168" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C1QBP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Binds to the globular heads of C1q molecules activating the classical pathway of complement.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs3786054, localized in an intron (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-pathogens-08-00168" ref-type="bibr">138</xref>,<xref rid="B140-pathogens-08-00168" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFTPA2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soluble pattern-recognition molecule that may neutralize IAV infection.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-rs1965708; Q223K (NonSyn).<break/>-rs1059046; T9N (NonSyn).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B145-pathogens-08-00168" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Galectin-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recognizes galactose-containing oligosaccharides present in the cellular plasma membranes and in viruses, such as IAV.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-rs4820294 (NCR).<break/>-rs13057866 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B147-pathogens-08-00168" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TMPRSS2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type II transmembrane serine protease family member which activates HA proteins of diverse human IAV in tissue culture cells. Deletion of <italic>Tmprss2</italic> in mice impairs the spread of H1N1 influenza viruses, including the pH1N1. Moreover, body weight loss and survival were less severe in <italic>Tmprss2</italic> mutant mice compared to wild type mice after infection with H3N2 IAV.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-rs2070788, localized in an intron (NCR).<break/>-rs383510, localized in an intron (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B149-pathogens-08-00168" ref-type="bibr">149</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Syn-synonymous, NonSyn-nonsynonymous, NCR-non-coding region (Intron, regulatory regions, promoter or UTR).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pathogens-08-00168-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pathogens-08-00168-t002_Table 2</object-id><label>Table 2</label><caption><p>Associations between SNPs and IAV vaccine responses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SNPs (Type)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine expressed as a response to infections or tissue injuries. It plays an important role in host defense through the stimulation of acute-phase responses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-rs1800796 (NCR).<break/>- rs2069861 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-12B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Cytokine that serves as a crucial inducer of Th1 cell development.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs3212227, located in 3&#x000b4;UTR (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN-B1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine released as part of the innate immune response against infection by viruses or other pathogens.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs1364613 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TNFRSF1A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine receptor, its interaction with TNF-&#x003b1; control cell survival, apoptosis, and inflammation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs4149621 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-1R1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine receptor involved in inflammatory and immune responses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs3732131, located in 3&#x000b4;UTR (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-10RB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine receptor that mediates the activation of the JAK/STAT signaling pathway leading to the expression of ISG.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs3171425, located in 3&#x000b4;UTR (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-2RA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This cytokine receptor is important for the signaling pathway leading to immune cell differentiation and function.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-rs2228150 (Syn). -rs12722605 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-10RA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine receptor that is involved in the inhibition of the synthesis of several proinflammatory cytokines.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-rs4252249 (Syn)<break/>-rs4252243 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-12RB2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine receptor that plays a role in Th1 cell differentiation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs2307153; D465G (NonSyn).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-1RN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine receptor which modulates a variety of immune and inflammatory responses related with IL-1.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-rs315952 (Syn).<break/>-rs315951 located in 3&#x000b4;UTR (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TNFRSF1B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine receptor involved in the recruitment of anti-apoptotic proteins.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs5746026; K232E (NonSyn)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-pathogens-08-00168" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBL-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This calcium-dependent protein that plays an important role in innate immunity, and activates the lectin complement pathway.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs1800450; G54D (NonSyn)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B165-pathogens-08-00168" ref-type="bibr">165</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-28B (IFNL3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type III IFN molecule, with brad functions in antiviral responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs8099917 (NCR).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B153-pathogens-08-00168" ref-type="bibr">153</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Syn-synonymous, NonSyn-nonsynonymous, NCR-non-coding region (Intron, regulatory regions, promoter or UTR). IIV: inactivated seasonal vaccine. IL-6, interleukin 6. IL-12B, interleukin 12. IFN-B1, interferon beta 1 (IFN&#x003b2;). TNFRSF1A, TNF receptor superfamily member 1A. IL-1R1, interleukin 1 receptor type 1. IL-10RB, interleukin 10 receptor subunit beta. IL-2RA, interleukin 2 receptor subunit alpha. IL-10RA, interleukin 10 receptor subunit alpha. IL-12RB2, interleukin 12 receptor subunit beta 2. IL-1RN, interleukin 1 receptor antagonist. TNFRSF1B, TNF receptor superfamily member 1B. MBL-2, mannose binding lectin 2. IL-28 B or IFNL3, interferon lambda 3.</p></fn></table-wrap-foot></table-wrap></floats-group></article>